



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  A61K 37/02, 37/26, 37/43 A61K 39/00		A1	(11) International Publication Number: WO 92/18147  (43) International Publication Date: 29 October 1992 (29.10.92)									
<p>(21) International Application Number: PCT/US92/03086</p> <p>(22) International Filing Date: 15 April 1992 (15.04.92)</p> <p>(30) Priority data:</p> <table> <tr> <td>687,691</td> <td>19 April 1991 (19.04.91)</td> <td>US</td> </tr> <tr> <td>837,347</td> <td>14 February 1992 (14.02.92)</td> <td>US</td> </tr> <tr> <td>841,931</td> <td>25 February 1992 (25.02.92)</td> <td>US</td> </tr> </table> <p>(71) Applicant: AFFINITY BIOTECH, INC. [US/US]; 305 Chelsea Parkway, Boothwyn, PA 19061 (US).</p> <p>(72) Inventors: OWEN, Albert, J. ; 827 Sharon Circle, West Chester, PA 19382 (US). YIV, Seang, H. ; 800 Rockwood Road, Wilmington, DE 19802 (US). SARKAHIAN, Ani, B. ; 275 Bryn Mawr Avenue, F-8, Bryn Mawr, PA 19010 (US).</p>		687,691	19 April 1991 (19.04.91)	US	837,347	14 February 1992 (14.02.92)	US	841,931	25 February 1992 (25.02.92)	US	<p>(74) Agent: ELDERKIN, Dianne, B.; Woodcock Washburn Kurtz Mackiewicz &amp; Norris, One Liberty Place - 46th Floor, Philadelphia, PA 19103 (US).</p> <p>(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, RU, SD, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent).</p> <p>Published:  <i>With international search report.</i>  <i>With amended claims and statement.</i></p>	
687,691	19 April 1991 (19.04.91)	US										
837,347	14 February 1992 (14.02.92)	US										
841,931	25 February 1992 (25.02.92)	US										

## (54) Title: CONVERTIBLE MICROEMULSION FORMULATIONS

## (57) Abstract

There is provided a water-in-oil (w/o) microemulsion which readily converts to an oil-in-water (o/w) emulsion by the addition of aqueous fluid to the w/o microemulsion, whereby any water-soluble biologically-active material in the aqueous phase is released for absorption by the body. The w/o microemulsion is particularly useful for storing proteins and the like for long periods of time at room temperature and above until they are ready for use, at which time the addition of aqueous fluid converts the microemulsion to an o/w emulsion and releases the protein.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TC	Togo
DK	Denmark			US	United States of America

## CONVERTIBLE MICROEMULSION FORMULATIONS

### **Field of the Invention**

This is a continuation-in-part of the application filed February 14, 1992 entitled "CONVERTIBLE MICROEMULSION FORMULATIONS" by Albert J. Owen; Seang H. Yiv and Ani B. Sarkahian, Attorney Docket No. AFBI-0200 which in turn is a continuation-in-part of application Serial No. 687,691, filed April 19, 1991.

This invention relates to microemulsions, and methods of making and using the same. More particularly, it relates to certain unique microemulsion formulations which are phase reversible (i.e., "convertible" as defined below), methods for making and storing them, and their use in administering drugs, proteins, and like biologically-active materials, including therapeutically-active ones.

As used herein, the microemulsions of this invention are self-emulsifying stable dispersions of oil and water, stabilized by interfacial films of surface-active molecules. These microemulsions are also characterized by their small average particle sizes, generally less than about 0.1 micron, by their wide range of temperature stability, typically from about 5°C to 50°C, and they appear to be thermodynamically-stable, i.e., stable indefinitely over this range. They are also relatively insensitive to the pH or ionic strength of the aqueous internal phase.

These microemulsions are further characterized in that they form spontaneously without the need of high shear

- 2 -

equipment, as distinct from conventional emulsions (macroemulsions) which must be prepared by the input of significant amounts of energy, and which are thus subject to extremes of temperature, pressure, and shear, resulting 5 in damage to the contents of the emulsion. For further discussion of these systems, see "Microemulsions," M. Kahlweit, *Science*, 240:617-621 (1988).

By the term "convertible" or "phase reversible", as used herein to describe the microemulsions of this 10 invention, is meant a microemulsion formulation capable of being changed from a water-in-oil (w/o) system to an oil-in-water (o/w) system by the addition of water to the former, as described in further detail below.

Also, "conversion," as used herein, is intended to 15 define in particular the reversal of a w/o emulsion to form an o/w emulsion, as distinct from the term "inversion", as used in the art, which describes principally the change of a w/o emulsion to a water-in-oil-in-water (w/o/w) formulation.

## 20 Background of the Invention

The preparation and use of microemulsions in the formulation of drugs, proteins, and the like are known in the art. See, for example, U.S. Patent 3,989,843, which discloses the application of microemulsions to medical 25 formulations. Also, in *Eur. J. Biochem.*, Samama et al., 163(3):609-617 (March 16, 1987) describe liver alcohol dehydrogenase in ionic w/o microemulsions, while Lee et al. describe the extraction of epoxide cyclase, using various ionic microemulsions, in *FEBS Lett.*, 244(2):347-50 (Feb. 30 27, 1989). In each case, however, there is no teaching or suggestion that these microemulsions are phase reversible.

U.S. Patents 4,931,210; 4,857,506; 4,714,566; and 4,590,086, on the other hand, disclose methods of preparing water-in-oil emulsions which are then inverted to form 35 well-known water-in-oil-in-water phase (w/o/w) emulsions. These complex preparations, however, are macroemulsion

- 3 -

formulations requiring high shear energy to prepare, and the resulting product is a w/o/w emulsion which actually comprises a w/o emulsion mixed into an aqueous phase in such a way that the first internal aqueous phase does not mix with the second continuous aqueous phase.

Emulsion systems for delivery of lipophilic agents via oral, parenteral, or local cutaneous administration and for transdermal delivery of the polypeptide hirudin are disclosed in U.S. Pat. No. 4,719,239 to Muller et al.

10 Microemulsion systems containing drugs having a good hydrophilic/lipophilic balance for transdermal delivery are disclosed in GB Application 2,098,865. These references fail to disclose the use of a water-in-oil microemulsion for the mucosal delivery of a water-soluble active agent,

15 such as proteins and peptides.

Emulsion systems have also been used as vaccine adjuvant systems, particularly water-in-oil emulsions. The strength of the immune response and the speed with which it is evoked can be modified by the nature of the liquid

20 matrix of the vaccine. One widely-used example of such a system is Freund's adjuvant, which consists of paraffin oil and a surfactant, mannide mono-oleate. These adjuvant emulsions, due to their thermodynamic instability, must be emulsified with a solution containing the immunogen just

25 prior to injection of the vaccine. In addition, the paraffin oil in the adjuvant can lead to inflammation of the injection site and formation of granulomas. These two effects are greatly enhanced if immune stimulators are also employed. The oil and immune stimulators are helpful,

30 however, in that they stimulate immune response by enhancing the activity of macrophages. These macrophages engulf the emulsion droplets and process the immunogen at the site of the injection. It would, therefore, be beneficial to be able to produce a vaccine adjuvant system

35 which has a prolonged stability and thus, a prolonged shelf life in its prepared microemulsion state, and which can be

- 4 -

formulated with a biodegradable oil which would not stimulate granuloma production.

There is a continuing need for new and improved delivery systems for biologically active materials. Many of the therapeutic agents emerging from the biotechnology revolution, as well as some older drugs such as insulin and calcitonin, consist of large-molecule proteins. These drugs must now be injected into the patient because they are unable to survive the digestive process and do not readily pass through the mucosal lining of the gastrointestinal tract and enter the bloodstream. A new drug delivery system that would enable proteins to enter the bloodstream through, for example, the lining of the digestive system would be of great benefit.

Improved drug delivery systems could also provide much improved convenience for patients. For example, calcitonin is a generic peptide hormone used for treatment of osteoporosis and other diseases involving bone loss. Osteoporosis affects 24 million Americans, including 2/3 of the women past menopause. Currently, most calcitonin is delivered by injection. Calcitonin treatment for osteoporosis requires long-term administration with low but frequent doses of the drug. An oral or suppository formulation of calcitonin would offer great advantages to patients undergoing such treatments.

#### **Summary of the Invention**

In accordance with the present invention, there is now provided a composition comprising a highly stable water-in-oil microemulsion containing biologically, including therapeutically, active water-soluble materials in its internal aqueous phase, which water-soluble materials are controllably releasable when needed just prior to administration by the ready conversion of the microemulsion into an oil-in-water emulsion by the addition of water to form a continuous aqueous phase.

The invention also relates to the preparation of such microemulsions and their use in the administration of

- 5 -

biologically and therapeutically active water-soluble materials.

One aspect of the invention is the storage or maintenance of materials, such as proteins and peptides, in a solubilized state at temperatures or conditions at which they would otherwise be unstable. For example, it has been found that some proteins can be stored dissolved in the aqueous phase of the w/o microemulsions at temperatures at which the protein would be unstable if stored merely as an aqueous solution. Such proteins may be stored in a w/o microemulsion of this invention until ready to be used, at which time water is then added until an o/w emulsion has formed, which emulsion is then administered orally or by injection. Also, the stored w/o microemulsion can be administered to the body wherein it is converted to an o/w emulsion by the addition of bodily fluids. In this manner, storage problems are lessened or eliminated.

Typical of the storage times for drugs, proteins, and the like, which may be achieved with the compositions of this invention, are times anywhere from about 1 to 48 hours, preferably 16-24 hours up to several, i.e., 3-12, weeks or months, at temperatures of from about room temperature, i.e., about 20°C, up to the temperature where the microemulsion breaks, generally in the range of about 25 50-70°C, preferably below about 40°C. Temperatures below room temperature can, of course, be used.

In a further aspect of this invention, it has been found that, unexpectedly, if a w/o microemulsion of this invention containing, for example, a water-soluble drug in the internal aqueous phase, is administered directly to the body of animals, including humans, the body fluids themselves are sufficient to convert the w/o microemulsion to an o/w emulsion, thereby slowly releasing the drug in situ. This is particularly advantageous over pre-conversion with water in that because body fluids are employed, the total volume of liquid administered is smaller. This method is particularly useful in

- 6 -

administration into the colon or intestines of such drugs as peptides, proteins, or other molecules with bonds that are readily attacked by enzymes, where the oil protects the drug in the intestines until it is slowly released as the 5 body fluids convert the emulsion. In the case of calcitonin, for example, if it is administered into the colon as just an aqueous solution, colon enzymes destroy the drug before it is absorbed, whereas with the microemulsion formulations of this invention, the 10 calcitonin is protected from the enzymes until it is slowly released by hydration within the body.

In one particular embodiment of the present invention the w/o microemulsion system is formulated such that, upon conversion with additional water, an o/w 15 microemulsion is formed. Such a system is advantageous in that the converted system has a small particle size. In another embodiment of the present invention, the microemulsion system is formulated as a solid at room temperature which has surprisingly been found to enhance 20 drug uptake and activity for gastro-intestinal delivery.

A particular embodiment of the present invention is the use of a w/o microemulsion as a vaccine adjuvant system. The immunogen is carried in the aqueous phase of the microemulsion adjuvant system, which when introduced 25 into the body and contacted with aqueous bodily fluids, undergoes conversion to form an oil-in-water emulsion.

"Administration to the body", as used herein for systems that convert to macroemulsions, includes any non-intravenous method such as intramuscular, subcutaneous, 30 oral, rectal, or peritoneal means. More specifically, the w/o microemulsion is administered parenterally, enterally, or via any other mucous membrane. Systems that convert to microemulsions can also be administered intravenously and intraarterially.

35 In yet another embodiment of this invention, it has been determined that these w/o micro emulsions may also be used to formulate topical salves which are highly

- 7 -

advantageous in that they remain moist on the skin for long periods of time without drying and crumbling.

#### **Brief Description of the Drawings**

Fig. 1 is a phase diagram of an embodiment of the 5 present invention depicting the water-in-oil microemulsion region wherein the oil is Captex 200, the aqueous phase is a 0.9% wt. NaCl aqueous solution, and the surfactant mixture is Capmul MCM:Myverol 18-92:Cremophor EL.

Fig. 2 is a phase diagram of an embodiment of the 10 present invention depicting the water-in-oil microemulsion region wherein the oil is Captex 200, the aqueous phase is 0.9% wt. NaCl aqueous solution, and the surfactant mixture is Capmul MCM:Centrophase 31:Tween 80.

Fig. 3 is a phase diagram of an embodiment of the 15 present invention depicting the water-in-oil microemulsion region wherein the oil is Captex 200, the aqueous phase is 0.9% wt. NaCl aqueous solution, and the surfactant mixture is Capmul MCM:Centrophase 31:Cremophor EL.

Fig. 4 is a phase diagram of an embodiment of the 20 present invention depicting the water-in-oil microemulsion region wherein the oil is Whitepsol H-15, the aqueous phase is a 20% wt. Sorbitol in 0.9% wt. NaCl aqueous solution, and the surfactant mixture is Capmul MCM:Myverol 18-92:Tween 80.

Fig. 5 is a phase diagram of an embodiment of the 25 present invention depicting the water-in-oil microemulsion region wherein the oil is MYVACET 9-45K, the aqueous phase is 0.9% wt. NaCl aqueous solution, and the surfactant mixture is Capmul MCM:Myverol 18-92:Cremophor EL.

#### **30 Description of the Invention**

The biologically active material composition of this invention comprises, at a minimum, (1) an aqueous phase; (2) a pharmaceutically-acceptable oil, or mixtures thereof; (3) an oil-dispersible surfactant, or mixtures thereof; and 35 (4) a water-soluble biologically active material or combination of materials. In addition, there may optionally be included such other adjuvants as stabilizers,

- 8 -

coloring agents, oil soluble drugs and the like. Each of these components and adjuvants must be suitable for use in the subject and will usually be food grade and/or pharmaceutically-acceptable materials. Any drugs will be 5 present in therapeutically-effective amounts. The compositions of the present invention are biologically compatible water-in-oil (w/o) microemulsions. These compositions are biologically compatible in that they are non-toxic and contain biodegradable or non-absorbable 10 materials. By non-toxic it is meant non-toxic dependent upon the route of administration to a subject, in that the toxicity of one route may not be equivalent to that of another route.

The microemulsions of the present invention are 15 created by the interplay between the surfactant or mixture of surfactants and the oil and aqueous phases. The surfactant or mixture of surfactants preferably have a hydrophilic-lipophilic balance (HLB) within a specified range. By "hydrophilic-lipophilic balance" is meant an 20 empirical quantity, on an arbitrary scale, which is a measure of the polarity of a surfactant or mixture of surfactants. See P. Becher et al., "Nonionic Surfactant, Physical Chemistry," Marcel Dekker, NY (1987), pages 439-456. It is a widely known and used term. The w/o 25 microemulsions can be solids including semi-solids, gels, or liquids at room temperature.

More particularly, the amount of the components should be such that the biologically-active material comprises from  $10^{-9}$  to 100 weight/volume %, based on the 30 volume of the aqueous phase. Generally, in the microemulsion system, the aqueous phase ranges up to about 60 volume percent; the oil content ranges from about 5 to about 99, preferably from about 10 to about 99 volume percent; the surfactant content ranges from about 1 to 35 about 70 volume percent.

The water content in the w/o microemulsions is up to about 20 volume percent, preferably up to about 30 volume

- 9 -

percent, most preferably up to about 40 volume percent, and in some cases as high as 60 volume percent of the microemulsion. In a preferred high aqueous phase content w/o microemulsion system, the aqueous phase content ranges 5 from about 20 to about 60 volume percent, preferably from about 30 to about 60, most preferably about 40-55%; the oil content ranges from about 5 to about 50 volume percent, preferably from about 5 to about 40, most preferably about 5-15%; the surfactant content ranges from about 5 to about 10 75 volume percent, preferably from about 20 to about 65, most preferably about 40-50%. In a preferred low aqueous phase content w/o microemulsion system, the aqueous phase should comprise no more than about 20%, preferably the aqueous phase content ranges from about 0.1 to about 20 15 volume percent, most preferably about 0.1-15%; the oil content ranges from about 30 to about 99 volume percent, preferably about 50-90%; the surfactant content ranges from about 1 to about 70 volume percent, preferably about 2-50%. When the aqueous phase of the w/o microemulsion is below 20 about 20% volume, it is preferred to have a ratio of oil phase to low HLB surfactant, HLB below about 8, preferably below about 5, of at least 6:1, and preferably at least about 10:1. The water component of the aqueous phase can be partially or fully replaced by the incorporation of 25 another polar, biologically compatible solvent such as polyhydrolic alcohols having at least 2 hydroxyl groups, glycerol, propylene glycol, and mixtures thereof, however it is preferred to have the aqueous phase consist of at least 30%, and most preferably 50% water. Thus, the term 30 "aqueous phase" as used herein is intended to encompass a phase comprising water, such polar solvents, and mixtures thereof. The aqueous phase may comprise, in addition to water (or other polar solvent) and active material, such other adjuvants such as, but not limited to, stabilizers, 35 coloring agents, modifiers, and the like, or salts ( e.g., when saline is used).

- 10 -

The formulation of a microemulsion having a high aqueous phase content is preferred in those situations where the biologically-active material has a relatively low solubility in water or where a relatively high quantity of 5 the biologically-active material is desired in the microemulsion system.

Adjuvants, such as preservatives, coloring agents, flavors or oil-soluble drugs, e.g., steroids, if any, should be included only in those amounts which will not 10 adversely affect the novel properties of the microemulsion, generally in amounts of from about 0 to 20% by volume, based on the total volume of the composition.

In the following description it will be understood that the nature of the oils and surfactants is not critical 15 beyond those particular qualifications set forth below, and may generally be any such known materials conventionally employed and which are accepted in the food and pharmaceutical industry.

The oil, or mixtures thereof, may be liquid at room 20 temperature, although in some cases, mild heating of a solid oil to form a liquid is acceptable. If injection is the preferred route of administration, the oil should be liquid at room temperature. Heating of an oil that is solid at room temperature is desirable for formulations 25 intended as suppositories, creams, salves, and in some cases as oral capsules. Illustrations of suitable oils for purposes of this invention include triesters of glycerol having from about 9 to 83, preferably 20-60, carbon atoms, and diesters of propylene glycol having from about 7 to 55, 30 preferably 15-40 carbon atoms, most preferably propylene glycol esters of capric and caprylic acids having from 19 to 23 carbon atoms. The triglycerides are further defined as short chain triglycerides having 9-15 carbon atoms, medium chain triglycerides having 21-45 carbon atoms, and long 35 chain triglycerides having above 45 carbon atoms. Short chain and medium chain, and preferably short chain, triglycerides are preferred for liquid w/o microemulsion

- 11 -

systems. The diesters of propylene glycols are further defined as short chain having from 7-11 carbon atoms, medium chain having from 15-31 carbon atoms, and long chain having above 31 carbon atoms. Examples of glycerol 5 triesters include natural, edible oils such as canola, corn, olive, sunflower and coconut oils, triacetin, the decanoic acid esters, and chemically-synthesized oils such as 1-oleyl-2,3-diacetyl glycerol. Diesters of propylene glycols include propylene glycol esters of capric and 10 caprylic acids, such as Captex 200® (Karlshamns Lipid Specialities, Columbus, OH) and other ester groups as described above for glycerol.

As shown in the data below, it has been found in another embodiment that, surprisingly, when a mixture of an 15 oil and mono and diglyceride surfactants, particularly Captex 200® and Capmul MCM®, manufactured by Karlshamns Lipid Specialities of Columbus, OH, as defined below, are used together, there is a significant enhancement in activity of the active ingredient. Therefore, depending 20 upon the nature of the drug, mixtures of oils and mono and diglycerides may be preferred.

The surfactant, or more preferably, the mixture of surfactants, should be chosen from those having a resulting HLB value in the range of from about 7 to 14, more 25 preferably 8 to 13. When a mixture of surfactants is employed, while some of the components may have a value outside the desired range, e.g., below about 5, it will be understood that by mixing in surfactants with HLB's greater than, e.g., about 9, the resulting combined HLB value will 30 be in the range of 7 to 14. Also, when a mixture is employed, it is desirable that at least one of these surfactants have a molecular weight of at least about 500, although this weight is not critical. It has been found that although some protein and peptide delivery systems 35 require the presence of certain surfactants, such as sterols or lecithin, the present w/o microemulsion systems do not require any particular surfactant or surfactant

- 12 -

mixture, and can be essentially free, that is containing less than about 0.05% wt. in the w/o micro emulsion, of any of the listed surfactants. However, to promote bioavailability of the active agent, certain surfactants 5 are preferred.

A mixture of surfactants is preferred when the w/o microemulsion has an aqueous phase content of greater than about 20% by volume. The mixture includes a high HLB surfactant or mixtures of high HLB surfactants, having a 10 HLB value of greater than 9 and preferably at least one surfactant having a HLB value greater than about 12. In some embodiments having a relatively high aqueous phase content above about 40% by volume, it is preferred to have at least one surfactant with a HLB greater than about 15, 15 and a low HLB surfactant having a HLB value below about 5, which together have an average HLB value of from about 7 to 14. Further, the surfactant should desirably be highly oil-soluble or oil-dispersible, and the ready addition of the surfactant to the oil thus makes for easier processing.

Surfactants which may be employed in our 20 compositions include both ionic agents, i.e., cationic, anionic or zwitterionic, and non-ionic agents, or mixtures thereof. Examples of cationic surfactants include cetyltrimethylammonium bromide, cetylpyridinium 25 chloride and other salts of these surfactants.

Examples of anionic surfactants include C<sub>8-32</sub> fatty acids and salts thereof; cholic acid and derivatives thereof such as deoxycholate, and its salts, ursodeoxycholic acid, and taurocholic acid; C<sub>8-56</sub> diesters of 30 tartaric acid; phospholipids such as phosphatidic acid and phosphatidyl serine; C<sub>5-29</sub> monoesters of lactic acid; C<sub>8-20</sub> sulfonates, including alkyl-, olefin-, and alkylaryl derivatives; tridecyl- and dodecylbenzene sulfonic acids; and C<sub>5-33</sub> sarcosine and betaine derivatives.

Zwitterionics include such phospholipids as 35 lecithin, phosphatidylethanolamine, and sphingomyelins.

- 13 -

Among the non-ionic surfactants which may be employed are ethoxylated castor oil; C<sub>5-29</sub> mono-glycerides and ethoxylated derivatives thereof; C<sub>15-60</sub> diglycerides and polyoxyethylene derivatives thereof having 1 to 90 POE groups; C<sub>10-40</sub> esters (10-40 carbon atoms in the alcohol) of long chain fatty acids (fatty acids having 16 carbon atoms and above); C<sub>10-40</sub> alcohols; sterols such as cholesterol, ergosterol, and C<sub>2-24</sub> esters thereof; C<sub>8-96</sub> ethoxylated fatty esters; C<sub>14-130</sub> sucrose fatty esters; and C<sub>20-130</sub> sorbitol and 10 sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups, e.g., polyoxyethylene sorbitan monooleate, sorbitol hexaoleate POE (50). Of these, mono- and di-glycerides, or mixtures thereof, are preferred as low 15 HLB surfactants and the sorbitol and sorbitan compounds as high HLB surfactants. More specifically, preferred low HLB surfactants include C<sub>9</sub> to C<sub>13</sub> monoglycerides (HLB about 4-7), C<sub>19</sub> to C<sub>25</sub> diglycerides of mono and poly unsaturated fatty acids (HLB about 3-5), C<sub>15-C<sub>23</sub></sub> diglycerides (HLB about 20 4-6), and C<sub>35</sub> to C<sub>47</sub> diglycerides of mono and poly unsaturated fatty acids (HLB about 2.5-4.5); preferred high HLB surfactants include ethoxylated castor oil (HLB about 10-16) and the sorbitan surfactants with HLB from about 10-18. Short chain monohydroxyl alcohols, such as C<sub>1</sub> to C<sub>6</sub> are 25 not employed as surfactants in these systems due to toxicity factors.

As stated above, the molecular weight of these surfactants is not critical, but it is desirable that at least one of them have a molecular weight of at least about 30 500, more preferably greater than about 750.

The water-soluble active material to be incorporated in the internal aqueous phase of the w/o microemulsion may be any biologically active material, particularly water-soluble proteins, peptides and other 35 pharmaceutically-active compounds, i.e., drugs, and compounds which may have use as diagnostic agents. Vitamins and other food supplements which are not commonly defined

- 14 -

as being "therapeutic" are not within the definition of the active agent. Illustrations of proteins which may be advantageously formulated, particularly for prolonged storage, include enzymes, such as horseradish peroxidase, 5 alkaline phosphatase and derivatives thereof; and other unstable proteins which tend to undergo inactivation during storage at elevated temperatures, such as cytokines, hemoglobin, interleukins, and the like. Peptides including polypeptide hormones such as calcitonins, insulins, and the 10 like are suitable for incorporation.

Other active agents that can be used in the w/o microemulsion system include peptides which may be satisfactorily employed include such pharmaceutically-active peptide drugs as desmopressin (1-15 desamino-8-D-arginine vasopressin). Drugs that can be employed in this system are water soluble drugs which are characterized by having low oral bioavailability. Examples of some of the drugs that can be employed include: anticoagulants, such as heparin or its derivatives; 20 antimicrobials, such as penicillin G, carbenicillin, meziocillin and other poorly absorbed penicillin derivatives; cephalosporins, such as cephalothin, cefoxitin, cefotaxime and other molecules in this series normally administered by injection; antineoplastic drugs, 25 such as fluorouracil, cytarabine, azauridine, thioguanine, vinblastine, vincristine, and bleomycin; anti-inflammatories, such as aurothioglucose and gold sodium thiomalate; and antiparasitic drugs, such as suramin and mebendazole.

30 Other active agents include RGD peptides, hematoregulatory peptides, vasopressin, collagenase inhibitors, angiotensin inhibitors, mammalian growth hormones, erythropoietins, interleukins (e.g. IL-2, 3, 4 and the like), clotting factors (e.g. factors VII, VIII, 35 IX) colony stimulating factors (e.g. G-CSF, GM-CS, M-CSF), hypothalamic releasing peptides (e.g. growth hormone releasing peptides, gonadotropin releasing factors),

- 15 -

interferons, tissue plasminogen activators, atrial natriuretic peptides, tumor necrosis factor, antibodies, antibody fragments, clotting factors, dismutases, vaccine, immunoregulators, HIV protease inhibitors, neurotrophic factors (e.g. nerve growth factors), peptide and protein mimetics, and angiotensin II antagonists.

The present invention also provides for formulations incorporating small peptides, from about 2 to about 10, more preferably from about 2 to about 6 amino acid moieties. One group in particular, the fibrinogen receptor antagonists (RGD containing peptides) are tetrapeptides with an average molecular weight of about 600. These peptide antagonists are highly potent platelet aggregation inhibitors at plasma levels as low as 1 pmol/ml. A preferred fibrinogen antagonist is the peptide cyclo(S,S)-N<sup>a</sup>-acetyl-Cys-(N<sup>a</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub> prepared by the method of Ali et al., published application EP 0 341 915 whose disclosure is herein incorporated by reference in its entirety. Also preferred is the peptide cyclo(S,S)-(2-mercaptophenyl)-(N<sup>a</sup>-methyl)Arg-Gly-Asp-(2-mercaptophenylamide which may be prepared by the method disclosed in published EPO 0423212, Application No. 90311537.6 whose disclosure is herein incorporated by reference in its entirety. The RGD peptides can generally be included into the microemulsion in an amount up to about 50 mg/ml of the aqueous phase.

Other fibrinogen antagonists useful in the present invention are those peptides disclosed in Pierschbacher et al., WO 89/05150 (US/88/04403); Marguerie, EP 0 275 748; Adams et al., U.S. Patent 4,857,508; Zimmerman et al., U.S. Patent 4,683,291; Nutt et al., EP 0 410 537; Nutt et al., EP 0 410 539; Nutt et al., EP 0 410 540; Nutt et al., EP 0 410 541; Nutt et al., EP 0 410 767; Nutt et al., EP 0 410 833; Nutt et al., EP 0 422 937; Nutt et al., EP 0 422 938; Ali et al., EP 0 372 486 Ohba et al., WO 90/02751 (PCT/JP89/00926); Klein et al., U.S. Patent 4,952,562; Scarborough et al., WO 90/15620 (PCT/US90/03417); Ali et

- 16 -

al., PCT US 90/06514, filed November 2, 1990; peptide like compounds as disclosed in Alig et al., EP 0 381 033; and Alig et al., EP 0 384 362; and the cyclic RGD peptides:

Ac-Cys-(NMe)Arg-Gly-Asp-Pen-NH<sub>2</sub>

5

|

, or

Ac-Cys-Asn-Dtc-Amf-Gly-Asp-Cys-OH

Dtc=4,4'Dimethylthiazolidine-5-carboxylic acid  
Amf=para - aminomethylphenylalanine

Larger peptides/polypeptide also useful in the present invention are those disclosed in Pierschbacher et 10 al., U.S. Patent 4,589,881 (>30 residues); Bittle et al., U.S. 4,544,500 (20-30 residues); and Dimarchi et al., EP 0 204 480 (>34 residues).

Also preferred are growth hormone releasing peptides, which are peptides generally of twelve amino 15 acids or less and effect the release of growth hormone. The growth hormone releasing peptides can be used in an amount up to about 75 mg/ml of the aqueous phase.

Exemplary of the class of growth hormone releasing peptides is the peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub> and 20 other peptides which cause the release of growth hormone by essentially the same mechanism as His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>. Another preferred growth peptide is Ala-His-D-Nal-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>. Growth hormone releasing peptides are disclosed, for instance, in Momany, U.S. Patent 25 4,411,890; Momany, U.S. Patent, 4,410,513; Momany, U.S. Patent 4,410,512; Momany, U.S. Patent 4,228,158; Momany, U.S. Patent 4,228,157; Momany U.S. Patent 4,228,156; Momany, U.S. Patent 4,228,155; Momany, U.S. Patent 4,226,857; Momany U.S. Patent 4,224,316, Momany U.S. Patent 30 4,223,021; Momany, U.S. Patent 4,223,020; Momany, U.S. Patent 4,223,019; Bowers et al., U.S. Patent 4,880,778; Bowers et al., U.S. Patent 4,880,777; Bowers et al., U.S. Patent 4,839,344; Bowers et al., U.S. Patent WO 89/10933 (PCT/US89/01829); Bowers et al., EP-A 398 961, Bowers et 35 al. EP-A 400 051, all of which are fully incorporated by reference.

- 17 -

The pharmaceutically-activ compounds employ d in the present invention also include immunog ns which can be incorporated into vaccine adjuvant systems. The immunogens which are acceptable include purified proteins and peptides 5 and derivatives thereof, and generally immunogens which have a weight average particle size in the range up to about 150 nm which therefore are capable of being maintained in the aqueous phase of the microemulsion.

The biologically active material is said to be a 10 "water-soluble" material. Those skilled in the art will readily understand by the list of representative active materials that they are soluble to an effective extent in an aqueous phase and have negligible solubility in an organic phase. The solubility of the active materials in 15 the aqueous phase at about 20°C is at least about 1 part per 100,000 parts and preferably at least about 1 part per 10,000 parts. To achieve this level of solubility the pH or ionic strength of the aqueous phase may be altered. The solubility of the active materials in organic materials, 20 such as those stated comprising the organic phase of the microemulsion, at about 20°C is less than about 10 parts per 1,000,000 parts and preferably less than about 1 part per 1,000,000 parts. The water:oil partition coefficient is greater than 10:1, advantageously at least about 50:1, 25 preferably at least about 100:1, and most preferably greater than about 1000:1. The water:oil partition coefficient is a commonly used quantity and refers to the ratio of the solubility of the material in water at about 20°C to the solubility of the material in a reference oil, 30 generally olive oil which is a mixture of triglycerides of saturated and unsaturated fatty acids esterified to glycerol, at about 20°C. The partition coefficient is determined by dissolving the active agent in an equal volume of water and olive oil (absent surfactant) and 35 determining the solubility in each phase. As us d herein, the reference oil is a U.S.P./N.F. grade olive oil

- 18 -

available from various chemical suppliers including Spectrum Chemicals Mfg. Corp., Gardena, CA.

The amount of active ingredient included in the internal aqueous phase may be varied considerably,

5 depending upon its solubility and activity, the use for which it is intended, the amount of emulsion to be employed, and the like. Generally, as stated above, active ingredients in the amounts of 10<sup>-9</sup> to 100% by weight/volume %, based on the volume of the internal aqueous phase,

10 provide a satisfactory formulation for most applications. The biologically active material will either be soluble in the w/o microemulsion or it will be soluble upon the conversion to the o/w emulsion upon the addition of water to the system.

15 The w/o microemulsions may be formulated with agents for enhancing mucosal absorption of peptides and proteins. These include bile salts such as trihydroxy bile salts, i.e. cholate, taurocholate, and glycocholate, dihydroxy bile salts, i.e. deoxycholate, taurodeoxycholate,

20 chenodeoxycholate, and ursodeoxycholate, triketo bile salts such as dehydrocholate. Non-ionic surfactants such as polyoxyethylene ethers with alkyl chain lengths from 12-18 carbon atoms and polyoxyethylene (POE) chain lengths from 2-60, p-t-octylphenoxy polyoxyethylenes with 2-60 POE

25 groups, nonylphenoxy polyoxyethylenes with 2-60 POE groups, polyoxyethylene sorbitan esters with 8-24 alkyl chain lengths and 4-80 POE groups, and 1-dodecylhexahydro-2H-azepin-2-one(azone, laurocapram) can be used. Anionic surfactants such as sodium dodecyl sulfate and dioctyl

30 sodium sulfosuccinate can be used. Lysolecithins containing saturated fatty acyl chains having 8-24 carbon atoms or unsaturated fatty acyl chains having 1 to 4 double bonds and 16-24 carbon atoms can be used. Mono/diesters of glycerol, such as medium chain fatty acid mono/di-esters

35 containing saturated fatty acids with 8-12 carbon atoms, and mono/di-glycrol esters of unsaturated fatty acids having 1 to 4 double bonds and 16-24 carbon atoms can be

- 19 -

used. Acylcarnitines, acylcholines and acylamino acids can be used, such as acylcarnitines having 12-20 carbon acyl groups and where the acyl groups have 0-4 double bonds, acylcholines such as acyl choline esters of fatty acids having 8-22 carbon atoms and 0-4 double bonds, and acylamino acids such as N-acyl amino acids and dipeptides having acyl groups with 8-24 carbon atoms and 0-4 double bonds and the amino acids having  $\alpha$  or  $\beta$  amino groups and a molecular weight less than 350. Additionally, mono and polyunsaturated fatty acids and their salts having 14-24 carbon atoms and 1-4 double bonds, and salicyclic acid and its sodium salt, sodium 5-methoxy-salicylate can be used.

The w/o microemulsions of this invention may readily be prepared by simply mixing together with mild agitation the selected components in the desired ratios at room temperature or at slightly elevated temperatures. As pointed out above, no high-energy mixing or application of heat is necessary, although limited use of each may be employed, if desired, to increase the rate of formation of the microemulsion. Moreover, the ingredients do not have to be added in any particular order other than that the active material be present in the aqueous phase as the emulsion is formed. Preferably, however, the surfactant should first be mixed with the oil phase, followed by the addition of water in the proper ratio. It is preferred to dissolve the active material in the water first, and then add this aqueous phase to the oil and surfactant components.

The size of the droplets, i.e., the number average diameter, in the resulting w/o microemulsion is usually 30 10-150 nanometers (nm), usually below 50-100 nm, with the majority of droplets below 100 nm, more preferably below 75. The particle size measurement is usually determined by laser light scattering techniques. The water-in-oil microemulsions are also characterized by their stable, 35 clear homogeneous appearance.

The amount of water or aqueous fluid, e.g. aqueous body fluid, necessary to convert the w/o emulsion to an o/w

- 20 -

emulsion when used, for example, for storing proteins, is not critical and may be determined routinely by titration of the microemulsion with excess water. Generally, however, it has been found that water in excess of about 1 5 to 33 times that of the volume of the emulsion is sufficient for this purpose.

Besides the volume of water added or provided by the body itself, other factors which control the rate of release of any given drug include pH, temperature, and 10 degree of agitation. Those skilled in the art will recognize that by varying these conditions in a generally known manner, the release of the drug can be slowed or increased as desired.

The microemulsion system of the present invention 15 can be formulated with a high melting oil, that is, an oil with a melting point above room temperature (22-23°C), preferably above about 30°C, in order to formulate a microemulsion which is a solid at room temperature. Also, high melting surfactants such as a C<sub>10-40</sub> ester of a long 20 chain fatty acid and alcohols having at least about 12 carbon atoms, wherein these surfactants have melting points above room temperature, preferably above about 30°C. Preferably, the microemulsion will melt at body 25 temperatures, generally between about 35-40°C. The amount of high melting oil and the melting point of that oil can vary, but the final composition containing the microemulsion is solid at room temperatures. The solid microemulsion system can be used as a suppository transport vehicle or as an oral transport vehicle. The oral 30 formulation is preferably in tablet or capsule form. The microemulsion can either be formulated directly with the high melting oil, or the microemulsion can be formulated first, after which the high melting oil is blended with the microemulsion. Such high melting oils are well known in 35 the art and include, for example, partially hydrogenated coconut oils, palm oils, cocobutter, hydrogenated peanut oil, and various hydrogenated veg table oils, along with

- 21 -

combinations thereof. Preferred oils include hydrogenated coconut and palm oils and mixtures thereof.

The w/o microemulsion system that is solid at room temperature (22-23°C) can be prepared using the high 5 melting oil directly with the other components during formulation. The solution of components is heated to a slightly elevated temperature of from about 25-60°C, preferably about 30-50°C, during mixing and cooled to a solid at room temperature. The final w/o microemulsion 10 system has component ranges within those previously stated for the liquid microemulsion systems. Preferred solid systems have from about 20-90%, preferably 30-60% w/w of a high melting oil having a melting point from about 85-120°F; from about 1-50%, preferably 3-30% w/w of the 15 aqueous phase, and 15-80%, preferably 23-60% w/w of a surfactant or surfactant mixture having an HLB range as set forth in this invention. Preferably, the surfactant is a mixture of surfactants containing 5-30%, preferably 8-20% w/w (of the microemulsion) of a surfactant having an HLB 20 greater than 8, and 10-50%, preferably 15-40% w/w (of the microemulsion) of a surfactant having an HLB lower than 8.

The w/o microemulsion system that is solid at room temperature can also be prepared by first preparing the w/o microemulsion without the high melting oil and dispersing 25 this microemulsion in the high melting oil. First, the w/o microemulsion is prepared according to the present invention. Then, the high melting oil is blended with the w/o microemulsion. Commonly this is accomplished at slightly elevated temperatures between about 25-60°C, 30 preferably about 30-50°C. The microemulsion is thereby dispersed within a matrix made of the high melting oil. The amount of high melting oil to microemulsion ranges from about 0.5:1 to about 2:1. This amount can vary beyond these ranges so long as a final dispersed microemulsion 35 system is produced which is a solid at room temperature. The high melting oil is typically admixed with a 1 w HLB surfactant, generally having a HLB below about 8, prior to

- 22 -

addition to the microemulsion in order to properly retain and disp rs the microemulsion in the high melting oil.

It has been surprisingly found that by taking a certain w/o microemulsion system of the present invention, 5 and adjusting it to have a higher effective HLB value, that the w/o microemulsion converts, upon addition of water, not just to an o/w emulsion as do all of the claimed w/o microemulsions, but rather to an o/w microemulsion. The higher HLB value is obtained in the present systems by the 10 addition of a modifier which allows the w/o microemulsion HLB level to be increased beyond its normal stability level without the breaking of the w/o microemulsion. The final HLB level of the surfactant or surfactant mixture of these w/o microemulsions is greater than about 7, and is 15 preferably from about 7 to about 16, most preferably from about 8-13. Modifiers found to be useful are incorporated into the aqueous phase of the microemulsion and include sorbitol, polyethylene glycol (PEG), mannitol, propylene glycol, and mono- and disaccharides. If proteins or 20 peptides are incorporated into the aqueous phase, then preferred modifiers are mannitol, sorbitol, and PEG.

The more modifier added to the w/o microemulsion, the higher the HLB can be raised in the system with the retention of a w/o microemulsion. This higher HLB level 25 allows for conversion to an o/w microemulsion. The precise amount of modifier and the precise amount of higher level HLB surfactant added to the w/o microemulsion is functionally determined by the presence of two end results: (1) the retention of the w/o microemulsion and (2) the 30 conversion to an o/w microemulsion upon addition of water.

The amount of modifier added to the aqueous phase of the w/o microemulsion depends on the desired final HLB. Typically, a 10-50%, preferably a 20-50%, most preferably a 20-30% by weight aqueous modifier solution, preferably a 35 sorbitol solution, can be employed as the modified aqueous phase for the w/o microemulsion. This sorbitol solution

- 23 -

can contain physiological buffers and saline or other salts.

The particle size of the w/o microulsion which converts to an o/w microemulsion is the same as aforementioned for the w/o microemulsions. The number average particle size of the converted o/w microemulsion is typically below about 100 nm, preferably between 10-100 nm, most preferably between 20-60 nm as determined by laser light scattering technique. The amount of water required to convert the w/o system to the o/w microemulsion can vary depending upon the composition of the w/o microemulsion. Typically the amount of water required ranges from about 1 to 10 times the volume of the w/o system. Larger amounts of water can be used to convert the w/o systems, and amounts up to 1000 times the volume of the w/o system, preferably about 3 to about 100 times the volume of the w/o system are used to convert to the o/w microemulsion.

These w/o converting to o/w microemulsion systems can be advantageously employed as transport vehicles for water soluble drugs which degrade in the oil phase, such as certain peptides, proteins, and immunogens used for oral or suppository formulations. Also, these formulations are preferred for intravenous and intraarterial administration. The risk of emboli formation is greatly reduced due to the exceedingly small particle sizes produced upon conversion with excess bodily fluid.

These w/o converting to o/w microemulsion formulations can also be used as nutritional lipid emulsions, and especially as total parenteral nutrition formulations. The w/o system can be converted using an aqueous phase containing water soluble nutrients to form lipid-in-water microemulsions just prior to administration.

The w/o microemulsions containing the biologically active material in the aqueous phase of the present invention are preferably administered parenterally, internally and via other mucous membranes such as nasally, rectally, vaginally, or via the colon. After

- 24 -

administration, the biological effect upon the animal caused by the active material can be measured or observed. The convertible microemulsion system enhances both the drug activation and uptake at the site of conversion. The 5 unique convertibility feature of the present microemulsions provides that the drug will be maintained primarily in the aqueous phase due to oil phase insolubility. This is advantageous in that certain active materials may become inactivated if dispersed within an oil phase or if 10 dissolved within an aqueous phase outside of an emulsion. Generally, such active materials as proteins and peptides employed in the present invention display a greater activity level when stored in the o/w microemulsion system as compared to their being stored for the same period of 15 time and under the same conditions in the same aqueous phase that is not contained within an emulsion system.

The oral administration of a biologically active material, contained within the w/o microemulsion drug delivery system of the present invention, can be in the 20 form of a capsule or tablet. The capsule is generally a starch or gelatin material. Certain active materials may be susceptible to the low pH environment of the stomach and should therefore be delivered to the higher pH environment of the intestinal system. Although such active materials 25 are beneficially delivered in suppository form, if oral delivery is desired, the capsule or tablet can be supplied with an enteric coating. Such coatings are well known in the art as are the methods of enterically coating a capsule or tablet. The method of producing an enterically coated 30 capsule using the w/o microemulsion system of the present invention is as follows. The w/o microemulsion containing the active agent is prepared and this composition is then placed into a capsule. The capsule is then coated with an enteric coating solution. The enteric coating solution 35 contains the polymeric enteric coating substance and solvents. The polymeric enteric coating substance is generally a pharmaceutically acceptable polymer that will

- 25 -

dissolv upon contact with intestinal fluids, pH of about 5.5 to 7.0, but will not dissolve in the low r pH stomach fluids. Enteric polymer coatings are readily available commercially, such as the Eastman® C-A-P™ (cellulose acetate phthalate) and C-A-T (cellulose acetate trimellitate) enteric coating materials available from Eastman Chemical Products, Inc. Various techniques are known to apply the entire polymer coating such as spray coating or immersion coating and several layers of the enteric substance may be required.

A preferred w/o microemulsion system for the delivery of a biologically active material, such as calcitonin, to the gastrointestinal tract is one which is both a solid at ambient conditions and which converts into an o/w microemulsion upon contact with an aqueous medium such as bodily fluids. An example of such a preferred system is one containing about 33-45% v/v, most preferably about 36-42%, of a composition containing a mix of triesters:diesters of glycerol and lauric acid having a melting point of about 33-36°C (an example being Witepsol H-15 which is a 90:10% wt. mixture of triesters:diesters with a small, less than 2% wt., amount of monoglycerides made by Huls of Germany); about 30-42% v/v, most preferably about 32-40%, of polyoxyethylene sorbitan monooleate (Tween 80, Sigma Corp.); about 5-10% v/v, most preferably about 6-9%, of mono-/di-glycerides of medium chain fatty acids, capric and caprylic (Capmul MCM, from Karlshamns Lipid Specialties, Columbus, OH); about 3.5-5.5% v/v, most preferably about 4-5% of a long chain monoglyceride, such as sunflower oil monoglycerides (Myverol 18-92); and about 3-25% v/v, most preferably about 5-20%, of an aqueous 20% w/v sorbitol in buffer solution containing the biologically active material. The drug content, pH, and ionic strength of the aqueous solution will vary depending on the composition that is most suitable for the hosted biological active material. If calcitonin is used, it is preferred to

- 26 -

employ up to about 1 mg of salmon calcitonin (from Bachem Co.) per gram of the microemulsion system.

A preferred w/o microemulsion system for the delivery of a biologically active material, such as 5 calcitonin, in a suppository form is one which is a solid at room temperature. An example of such a preferred system is one containing about 23-27% w/w propylene glycol esters of capric/caprylic acids (Captex 200 from Karlshamas Lipid Specialties, Columbus, OH); about 6-10% w/w mono- and 10 diglycerides of caprylic/capric acids (Capmul 8210 MCM from Karlshamas Lipid Specialties); about 1-2.5% w/w liquid lecithin from Central Soya (Centrophase 31); about 15-17% w/w polyoxyethylene glycerol triricinoleate (Cremophor EL from BASF); about 40-45% w/w partially hydrogenated palm 15 kernel, coconut and palm oils (HB-108 from Karlshamas Lipid Specialties), and about 5-7% w/w 100 mM acetate buffer, p.H.=4.2. When used in a calcitonin suppository, it is preferred to use about 980U salmon calcitonin (from Bachem Co.) wherein the weight of the final suppository is about 20 1.7g.

Another preferred system for delivery of the active material is a composition containing from about 5-80% v/v of a mixture of triesters:diesters of glycerol and lauric acid having a melting point of about 33-36°C (an example 25 being Witepsol H-15); about 15-50% v/v of polyoxyethylene sorbitan monooleate (Tween 80); about 3-11% v/v of mono-/di-glycerides of medium chain fatty acids, capric and caprylic (Capmul MCM); about 2-6% v/v of a long chain monoglyceride, such as sunflower oil monoglycerides 30 (Myverol 18-92); and about 6-42% v/v of an aqueous 25% w/w sorbitol and 25% w/w propylene glycol in buffer solution containing the biologically active material. The drug content, pH, and ionic strength of the aqueous solution will vary depending on the composition that is most 35 suitable for the hosted biological active material. This composition is preferred for the administration of such active agents as calcitonins, insulins, human growth

- 27 -

hormon s, fibrinogen receptor antagonists (RGD containing p ptides, such as cyclo(S,S)-N<sup>a</sup>-acetyl-Cys-(N<sup>a</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub>), and growth hormone releasing peptides, such as His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>.

5 As aforesated, in yet another embodiment, our microemulsions may be used to prepare non-drying topical, as opposed to transdermal, salves and ointments. These may readily be prepared by simply admixing a therapeutically-active amount of the emulsion with known topical petroleum bases or the like customarily employed for skin application, as long as these materials are compatible with the emulsion. The w/o microemulsion is ideally suited for wound care treatment where the dry epidermal skin layer, the stratum corneum or horny layer, is removed thereby exposing the aqueous-based dermal skin layer, as for example in burn wounds. The w/o microemulsion can also be used where the dermal skin layer is also partially removed. The w/o microemulsion, when contacted with the dermal or lower body layer converts to an o/w emulsion upon the 10 addition of aqueous bodily fluids. Preferably, proteases, such as serine, metallo, cysteine, aspartyl, and the like which degrade connective tissue proteins such as collagen and elastin and the like, along with growth factors are used as the active material to aid in the removal and 15 repair of skin tissue. Examples of growth factors include, for example, platelet derived growth factor, PDGF, epidermal growth factor, EGF, transforming growth factors, TGF $\alpha$  and TGF $\beta$ , and insulin-like growth factor, IGF-I and IGF-II, and the like. These active materials generally 20 have average particle sizes of greater than 1 to about 100, preferably from about 3 to about 30, nanometers. Typically, the molecular weight of these active materials 25 is at least about 5000 and up to over 40,000, preferably from about 5,000 to about 35,000. The average human epidermis pore size is below about 1 nm, and therefor the 30 active materials employed in the topical systems do not effectively traverse the epidermis skin layer.

- 28 -

Th topical microemulsion system acts as a r sevoir for pr viding a stable protein to the wound site. The topical microemulsion is preferably presented in the form of a solid, salve, or gel that can be easily removed from 5 the wound site by washing with aqueous fluid. Most preferably, the topical is presented as a solid or semi-solid (deforming upon application of pressure) to maintain the w/o microemulsion at the wound site for conversion and release of the drug.

10 A further embodiment of the present invention encompasses the use of the w/o microemulsion as a carrier system to be used in a vaccine adjuvant system. In such a vaccine adjuvant system, the immunogen is admixed into the aqueous phase. This aqueous phase is then admixed with the 15 oil phase which contains the surfactant. These adjuvant systems can also be formulated with an immuno-stimulator which are well-known in the vaccine adjuvant art. Such immuno-stimulators include such compounds as muramyl di-or tri-peptide and derivatives thereof; interferons, and 20 interleukins. The aqueous phase may also contain inorganic salts, buffering agents, preservatives, and the like, in addition to the immunogen.

The microemulsion vaccine adjuvant system of the present invention is characterized by its stability and 25 long shelf life, in comparison to emulsion adjuvant systems of the prior art. The use of the oils of the present invention, which are referred to as biodegradable oils, to formulate the microemulsion system provides benefits over previous emulsion adjuvant systems in that the production 30 of granulomas is believed to be decreased. The w/o microemulsion adjuvants can readily convert to oil-in-water emulsions when administered into the body which allows for the generation of macrophage stimulating oil droplets in situ. The smaller and more uniform size of the resulting 35 droplets also is expected to lead to a more reproducible response to a given immunogen.

- 29 -

The invention will now be illustrated by, but is not intended to be limited to, the following examples.

#### EXAMPLES

##### Formulation and Convertibility

5 Several formulations of the water-in-oil (w/o) microemulsions of this invention were prepared in which, by way of illustration, the components, their ratios, and the operating conditions selected to provide a convertible microemulsion, were varied somewhat as shown in the  
10 following examples. For convenience, a drug was not included in every instance, but it will be understood that any water-soluble drug, as defined above and as shown in some of the Examples, would be dissolved in the dispersed water phase.

15 The HLB value of each surfactant system and stability of each emulsion was then determined, as set forth below in each example.

20 For the purposes of these examples, the HLB values used were those specified by the suppliers of the surfactants; the resulting HLB of a mixture of surfactants was calculated on a volume basis.

In preparing each formulation, the following general procedure was employed:

25 Into a small vial was pipetted a measured amount of oil, followed by the addition of a surfactant, or mixture of surfactants, of a given HLB value. The vial was then shaken with a vortex mixer for a given number of minutes until the surfactant and oil were evenly mixed. A saline solution was then added to the oil/surfactant mixture and 30 the mixture shaken a few minutes until an optically clear w/o emulsion was recovered. Its stability is measured by periodic visual inspection for the presence of macroscopic phase separation, as shown by cloudiness or the formation of two distinct layers. Stable means the emulsion is clear 35 and single phase.

- 30 -

The physical characteristics of the microemulsions can be tested including such properties as viscosity, conductance and refractive indices.

**EXAMPLE 1**

5 In accordance with the foregoing general procedure, a w/o microemulsion was prepared employing the following components, amounts and ratios, and HLB values of the surfactants:

- 31 -

<u>Component</u>	<u>Composition</u>	<u>HLB Value</u>	<u>Amount (μL)</u>
Oil	Captex 200 <sup>1</sup>		870.0
Surfactant System	POE 50 Sorbitol Hexaoleate <sup>2</sup>	11.4	50.0
	Cremophor EL	13.5	50.0
Water	Saline (0.9wt.% NaCl)		30.0
<b>TOTAL</b>		<b>12.5</b>	<b>1000.0</b>

<sup>1</sup> Captex 200 - propylene glycol esters of capric/caprylic acids (Karlshamns Lipid Specialties, Columbus, OH)

TABLE 1

**Physical and Chemical Characteristics of Captex 200**

<sup>15</sup> Description: Diester manufactured by reesterification of fractionated coconut fatty acids (primarily caprylic and caproic) with propylene glycol.

CTFA Name: Propylene glycol dicaprylate/caprate

Free Fatty Acid (As Oleic): 0.03

Hydroxyl Number: 0.05

<sup>20</sup> Saponification Number: 329.7

Fatty Acid Composition:

Caproic	4.1
Caprylic	68.2
Capric	27.4
Lauric and higher	0.2

<sup>25</sup> <sup>2</sup> POE Sorbitol Hexaoleate - polyoxyethylene (50) sorbitol hexaoleate (ICI Americas, Inc. Wilmington, DE)

<sup>3</sup> <sup>3</sup> Cremophor EL - Polyoxyethylenglycerol Triricinoleate 35 DAC (BASF, Inc.)

<sup>30</sup> These components were mixed in a vortex mixer at 25°C for about 3 minutes to provide a clear stable w/o microemulsion.

- 32 -

Water was then added to the total composition in the ratio of 4:1 (v/v) to convert the microemulsion to an o/w emulsion.

**EXAMPLE 2**

5 In accordance with the procedures of Example 1, the following components were employed to form a w/o microemulsion:

<u>Component</u>	<u>Composition</u>	<u>HLB Value</u>	<u>Amount (μL)</u>
Oil	Captex 200		870.0
10 Surfactant System	Centrophase 31* Cremophor EL	4.0 13.5	10.5 89.5
Water	Saline (0.9 wt.% NaCl)		30.0
	TOTAL	12.5	1000.0

15 \* Centrophase 31 - lecithin (mol. wt. - 800) (Central Soya, Fort Wayne, IN).

These components were mixed in a vortex mixer at 25°C for about 6 minutes to provide a clear w/o microemulsion which was stable, at both 25°C and 50°C.

20 Water was then added to the total composition in the ratio of 4:1 (v/v) to convert the microemulsion to an o/w emulsion.

**EXAMPLE 3**

25 In accordance with the procedures of Example 2, but substituting 54.5 μL of Tween 80 (polyoxyethylene- sorbitan monooleate, Sigma Corp.) (HLB = 15) for Cremophor EL, and increasing the amount of Centrophase 31 to 45.5 μL to provide an average HLB value of 10.0, a w/o microemulsion was formed and converted to an o/w emulsion.

30 **EXAMPLE 4**

In accordance with the procedures of Example 1, the following components were employed to form a w/o microemulsion:

- 33 -

<u>Component</u>	<u>Compositi n</u>	<u>HLB Valu</u>	<u>Amount (μL)</u>
Oil	Captex 200		861.3
5 Surfactant System	Capmul MCM*	5.0	8.7
	Centrophase 31	4.0	10.5
	Cremophor EL	13.5	89.5
Water	Saline (0.9 wt.% NaCl)		30.0
TOTAL		9.0	1000.0

10 \* Capmul MCM - mono - and diglycerides of medium-chain fatty acids (capric and caprylic) (Karlshamns Lipid Specialties, Columbus, OH).

These components were mixed in a vortex mixer at 25°C for about 3 minutes to provide a clear w/o microemulsion having a particle size of 25 nm (number 15 average) and a stability from 5°C to 50°C as measured by periodic visual inspection.

Water was then added to the total composition in the ratio of 4:1 (v/v) to convert the microemulsion and produce o/w emulsion.

#### 20 EXAMPLE 5

In accordance with the procedures of Example 2, but increasing the amount of water (saline) from 30 to 150 μL to provide 15% water in the formulation, and adjusting the amounts of the other components accordingly (oil - 350 μL; 25 Centrophase 31 - 52.6 μL; Cremophor EL - 447.4 μL), the w/o microemulsion satisfactorily converted to an o/w emulsion. In this formulation, the ratio of oil-to-water was 2.3:1, and that of surfactant-to-water plus oil was 1:1.

#### EXAMPLE 6

30 In accordance with the procedures of Example 4, but altering the amount of Capmul surfactant, first to 4.35 μL (final HLB = 10.2), and then to 17.4 μL (final HLB = 7.7), convertible microemulsions were also obtained.

- 34 -

**EXAMPLE 7**

In accordance with the procedures of Example 4, but substituting 8.7  $\mu$ L of 1-monocapryloyl-rac-glycerol, or 8.7  $\mu$ L of Dicaprin (an equimolar mixture of 1,2- and 5 1,3-diglyceride of Capric acid), for the Capmul MCM surfactant, satisfactory convertible microemulsions were also obtained.

**EXAMPLE 8**

In accordance with the procedures of Example 2, but 10 substituting Myverol 18-92 (glycerol monolinoleate; HLB value - 3.8-4.0) for the Centrophase 31 surfactant of that surfactant system, and mixing the components for 3 minutes, there was obtained a w/o microemulsion which, when water was added (4:1 v/v), converted to an o/w emulsion. The HLB 15 of the surfactant mixture in this formulation was 9.0.

**EXAMPLE 9**

In accordance with the procedures of Example 4, but substituting 861.3  $\mu$ L of Myvacet (1-oleyl-2,3-diacetyl 20 glycerol); (Eastman Chemical Products, Inc., Kingsport, TN) for the Captex 200 as the oil, there was obtained a satisfactory w/o microemulsion which, upon addition of water to the total composition (in the ratio of 4:1 v/v), converted to an o/w emulsion. The HLB of the surfactant mixture in this formulation was 9.0.

**25 Stability Data**

In order to demonstrate the stability of the compositions of this invention at elevated temperatures for purposes of storing the same for long periods of time, a series of microemulsions was prepared in accordance with 30 this invention, following the general procedures of Example 2. In Example 10, the protein horseradish peroxidase (HRP), was stored for given times and temperatures, then assayed *in vitro*, as shown in this example.

**EXAMPLE 10**

35 This example illustrates the incorporation of a protein, namely the enzyme horseradish peroxidase (HRP), in

- 35 -

the convertible w/o microemulsion of this invention, and the stability of this resulting emulsion.

In accordanc with the general procedures above, an enzyme-containing microemulsion was prepared from the

5 following components:

<u>Component</u>	<u>Composition</u>	<u>HLB Value</u>	<u>Amount (μL)</u>
Oil	Captex 200		861.3
Surfactant System	Capmul MCM	5.0	8.7
	Centrophase 31	4.0	10.5
	Cremophor EL	13.5	89.5
Peroxidase Solution	(see Footnote 1)		30.0
TOTAL		9.0	1000.0

15 1 Peroxidase solution - 100 μL of HRP stock solution (1 mg/mL) in 400 μL of 0.9 wt.% saline (NaCl) solution.

These components were mixed in a vortex mixer at 25°C for about 2 minutes to provide a w/o microemulsion.

20 After storage for the specified time at 50°C, the microemulsion was then converted to an o/w emulsion by the addition of water. This was achieved by pipetting 30 μL of the microemulsion containing the horseradish peroxidase enzyme into 970 μL of 0.9 wt.% saline (NaCl) solution.

25 After conversion, the emulsion was then assayed for activity. This activity was compared with the activity of stock solutions of HRP which had been maintained at 50°C for the same time and then pipetted into saline (30 μL into 970 μL of saline) in the same manner as the microemulsion above. The stock HRP was first diluted to the same HRP concentration as in the aqueous phase of the converted 30 microemulsion.

#### A. Assay Procedure

The assay was carried out as follows:

1. Set spectrophotometer at 492 nm and 25°C.
2. Into the cuvette, pipet 2.97 mL OPD (O-35 phenylene diamine) buffer solution (1 tab. ~ 26 mL)

- 36 -

3. Establish blank at 492 nm.  
 4. Into the cuvette, pipet 25  $\mu$ L diluted control HRP solution. Mix and record the increase in absorbance at 492 nm for 5 minutes.

5 5. Same procedure is followed for microemulsion w/HRP solution. OPD = O-phenylene diamine

**B. Results:**

Percent activity was determined by using the following equation:

$$10 \text{ Percent Activity} = \frac{\text{Activity at time } t}{\text{Activity at time } 0} \times 100$$

The following table summarizes the results that were obtained from the assay for both Control HRP and 15 microemulsion containing HRP.

TABLE 2  
 PERCENT ACTIVITIES OF BOTH CONTROL HRP (STOCK SOLUTIONS)  
 AND MICROEMULSION CONTAINING HRP

		<u>% Activity</u>	
	<u>Time (Hours)</u>	<u>Control HRP</u>	<u>HRP in ME</u>
20	0	100	100
	3	76	77
	6	73	83
	24	20	68
25	27	20	68
	48	11	53

From the foregoing results, it will be seen that after 48 hours, the microemulsion containing HRP was much more active than the control HRP, which had lost most of 30 its activity by 48 hours. Thus, the microemulsion of this invention provides the distinct advantage of permitting long-term storage of proteins at elevated temperatures, whereas heretofore they had to be maintained at much colder temperatures to pr serve their stability.

**EXAMPLE 11**

A series of experiments was carried out in rats using the w/o microemulsions of this invention to evaluate them as a vehicle for the rectal delivery of the peptide 5 calcitonin, (used in the treatment of hypercalcemia by lowering Ca++ serum levels), whereby the body fluids of the rat would serve to convert the microemulsion to an o/w emulsion and thus release the calcitonin.

Formulations were produced which ranged from 3% to 10 15% (v/v) aqueous phase and which ranged from liquids to gels at room temperature. The formulations contained, in addition to the aqueous phase, one to three oils and a blend of two emulsifiers. Most formulations showed temperature stability over the range from 5°C to 50°C. 15 Three formulations with different oil blends were chosen for biological evaluation in juvenile, male rat model (Sprague-Dawley rats; 140-170 gm).

Rectal installation was compared with direct injections of calcitonin into the body. As shown by the 20 data below, rectal instillation of each of the three microemulsion calcitonin formulations tested produced a dose dependent lowering of serum calcium in the rat, thereby demonstrating that the w/o microemulsion had been converted in the colon, with the release of effective 25 amounts of active calcitonin. Control microemulsion preparations, on the other hand, which did not contain calcitonin, did not produce a significant change in serum calcium levels. Moreover, as shown below, incorporation of two oils plus coconut oil into the suppository to form a 30 semi-solid microemulsion improved the calcitonin response by more than tenfold over the basic liquid formulation containing a single oil.

**A. Formulations**

Three w/o microemulsion formulations were tested 35 which contained 3% v/v aqueous phase volume, and varying amounts of calcitonin/ml of emulsion. Two, Formulations A and B below, were formulated as liquids; the third

- 38 -

microemulsion (Formulation C) was formulated in semi-solid (suppository) form by addition of a high-melting coconut oil to the microemulsion. This formulation was a soft waxy solid at room temperature which melted at body temperature 5 to release calcitonin via the microemulsion.

**Key to Calcitonin Microemulsions Formulations:**

- A. The microemulsion of Example 2, plus calcitonin.
- B. The microemulsion of Example 4, plus calcitonin.
- 10 C. The microemulsion of Example 4, (1 volume,); to which is added 2 volumes of a mixture containing 1.8 volumes coconut oil and 0.2 volume Capmul MCM; plus calcitonin.

15 All calcitonin concentrations are given in units of biological activity per volume of final emulsion.

**B. Test Methods**

The calcitonin-containing, or just saline-containing, (control) microemulsions were 20 administered rectally to each of a group of 3 to 7 rats in a volume of 250  $\mu$ L. Blood samples were taken at time = 0, 1, and 2 hours after dosing. Serum calcium was measured after 1 and 2 hours because initial studies showed that this is when maximal calcitonin response was obtained. The 25 rats were anaesthetized throughout the entire procedure and were bled via the orbital sinus.

Serum was prepared from each blood sample and serum  $\text{Ca}^{+2}$  (free ionized calcium) levels were determined using a Beckman calcium clinical assay kit.

30 **C. Results**

The results of this study are shown in Table 2 which summarizes the activity of Microemulsions A, B and C.

- 39 -

TABLE 3

EFFECT OF RECTALLY-INSTILLED CALCITONIN  
MICROEMULSIONS ON SERUM CALCIUM LEVELS

5	Micro- emulsion	Calcitonin Content (units/ml)	No. of Animals	Change in Serum $\text{Ca}^{+2}$	
				at 1 Hr. after Treatment	After 2 Hrs. <sup>1</sup> (mg/dL) $\pm$ SD <sup>1</sup>
10	A	0	4	0.23 $\pm$ 2.55	1.92 $\pm$ 1.01
		60	7	-1.81 $\pm$ 2.50	-1.02 $\pm$ 1.65
		120	5	-1.11 $\pm$ 0.96	-1.60 $\pm$ 1.25
		240	5	-1.89 $\pm$ 1.27	-2.44 $\pm$ 1.29
15	B	0	4	-0.38 $\pm$ 1.58	0.73 $\pm$ 0.91
		10	4	-1.78 $\pm$ 0.78	-1.30 $\pm$ 0.50
		20	5	-1.98 $\pm$ 0.47	-2.36 $\pm$ 0.44
20	C	0	3	0.17 $\pm$ 0.09	0.67 $\pm$ 0.50
		10	4	-1.71 $\pm$ 0.51	-2.39 $\pm$ 0.36
		20	4	-1.82 $\pm$ 0.35	-2.23 $\pm$ 0.11
20	Preconverted	0	5	0.41 $\pm$ 0.13	0.47 $\pm$ 0.40
	B	20	5	-1.27 $\pm$ 1.07	-1.62 $\pm$ 1.29
	Saline	10	5	-0.13 $\pm$ 0.45	0.15 $\pm$ 0.33

<sup>1</sup> Ionized calcium in blood serum in units of milligrams of calcium (mg) per deciliter (100 mL) of serum  $\pm$  the standard deviation.

25 The results shown in Table 2 show the effectiveness of our microemulsions containing calcitonin in lowering serum calcium. Because of the higher response of ME-B compared to ME-A, we needed to determine that the lower response of ME-A was not due to deactivation of the  
30 calcitonin by the formulation itself. To determine this, 250  $\mu$ L of ME-A (60 Units/mL) and ME-A (0 Units/mL) were

- 40 -

injected SQ into 2 pairs of animals. The serum calcium fell an average of 3.2 mg/dL (milligrams/deciliter) in the calcitonin microemulsion-treated animals, and 0.3 mg/dL in the controls. This demonstrates the presence of active calcitonin in ME-A.

Another series of tests were performed to demonstrate the efficacy of these emulsions which were converted after storage but before administration into the rats. In accordance with these tests, Microemulsion B was formulated and stored at 5°C for 2 days, following which it was converted to an o/w emulsion by addition of water equal in amount to that of the total volume of the emulsion prior to rectal introduction into rats. As shown in Table 2, the calcitonin was generally effective after storage when pre-converted and then used, but not as effective as internal conversion within the colon.

The table also shows that incorporation of the mono- and diglycerides surprisingly produced a significant improvement in the response to calcitonin. A dose of 20 U/mL of ME-B produced a response similar to that previously obtained at 240 U/mL of ME-A, more than an order of magnitude improvement.

Rectal administration of the solid calcitonin microemulsion C produced responses that were equal to or greater than those seen with the B formulation.

The last line of Table 2 indicates that instilling a saline solution of calcitonin into the rectum produced no significant response.

#### EXAMPLE 12

The following example demonstrates that a non-convertible microemulsion wherein the surfactant HLB was 4.0, which was not effective in the rectal delivery of calcitonin.

- 41 -

A microemulsion was formulated as follows, using the general procedure of Example 1:

<u>COMPONENT</u>	<u>COMPOSITION</u>	<u>HLB VALUE</u>	<u>AMOUNT (μL)</u>
Oil	Captex 200		500
5 Surfactant	Centrophase 31 <sup>1</sup>	4.0	450
Water Plus Calcitonin	Buffered Solution <sup>2</sup>		50
Total		4.0	1000

<sup>1</sup> Liquid Soybean Lecithin

10 <sup>2</sup> Calcitonin amount = 240 units/mL

The resulting calcitonin-containing w/o microemulsion was introduced into the colons of rats in accordance with the general procedures of Example 11. A measurement of the ionized calcium in the blood showed no 15 significant decrease for the microemulsion system when compared to a control formulation with no calcitonin.

#### EXAMPLE 13

The following example demonstrates the production of w/o microemulsion systems which have relatively high water 20 concentrations. In accordance with the above mentioned general procedure, w/o microemulsions were prepared employing the following components, amounts and ratios (volumes below are in microliters):

- 42 -

Example	Surfactant			Oil		Aqueous Phase	
	Myverol 18-92	Tween 20	Centrolene A	Captex 200	Triacetin	1% NaCl Solut.	Water
1	270	230	--	100	--	400	--
2	250	200	50	100	--	400	--
3	240	180	80	50	50	--	400
4	260	160	80	50	50	--	400
5	260	160	80	50	50	--	500
6	260	160	80	50	50	--	600
7	260	160	80	50	50	--	720

Tween 20 is a laurate ester of sorbitol having a HLB value of about 16.7 purchased from Spectrum, New Brunswick, NJ. Centrolene A is a hydroxylated lecithin having a HLB value of about 9.5 manufactured by Central Soya, Fort

5 Wayne, IN.

#### EXAMPLE 14

A series of experiments was carried out using rats with the w/o microemulsion of this invention that are solid at ambient conditions to evaluate them as a vehicle for the 10 oral delivery of the peptide salmon calcitonin (used in the treatment of hypercalcemia by lowering  $\text{Ca}^{2+}$  and  $\text{PO}_4$  serum levels). The body fluids of the rat served to convert the microemulsion to an o/w emulsion which activated the drug and promoted drug uptake by the animal. The monitored 15 variables were  $\text{Ca}^{2+}$  and  $\text{PO}_4$ .

#### Formulations

The test preparations were prepared using a high melting point oil, in this case a mixture of hydrogenated coconut and palm oil. The oils used were obtained from 20 Karlshamns Lipid Specialties, USA, of Columbus, Ohio. The oils were labeled HB-95, HB-108, and HB-118 which corresponded to the trade names of HYDROKOTE 95, 108, and

- 43 -

118. The oils had an approximat melting point of 95, 108, and 118°F respectively.

The A group microemulsions were prepared by first formulating the microemulsion and then admixing the HB-108 oil with the microemulsion. The microemulsion components were mixed in a container at an elevated temperature of about 40°C to which was added the calcitonin contained in the acetate buffer. Once the microemulsion was formed, the HB-108 component containing 10% Capmul was added.

10 The B and C group microemulsions were prepared by formulating the microemulsion directly with the HB oil.

**FORMULATIONS**

	Group A1	Control (A1')
15 Dose	40 U/mL	0 U/mL
10% Capmul MCM in Captex 200	570 uL	1.71 mL
Cremophor EL	298 uL	894 uL
lecithin	35 uL	105 uL
20 100mm acetate buffer	92 uL	300 uL
calcitonin stock sol'n 10,000 U/ml	8 uL	-----
25 Total ME	1.0 mL	3.0 mL
10% Capmul in HB-108	1.0 mL	3.0 mL
Total volume	2.0 mL	6.0 mL

- 44 -

	Group B1	Control (B1')
<b>Dose</b>	<b>40 U/mL</b>	<b>0 U/ml</b>
Myverol 18-92	373 uL	746 uL
5 Tween 80	404 uL	808 uL
Capmul MCM	124 uL	249 uL
HB-95	725 uL	1.45 mL
10 100mm acetate buffer	365 uL	746 uL
10 calcitonin stock sol'n 10,000 U/mL	8 uL	-----
<b>Total volume</b>	<b>2.0 mL</b>	<b>4.0 mL</b>

	Group C1	Control (C1')
15		
<b>Dose</b>	<b>40 U/mL</b>	<b>0 U/ml</b>
Myverol 18-92	373 uL	746 uL
Tween 80	404 uL	808 uL
Capmul MCM	124 uL	249 uL
20 HB-118	725 uL	1.45 mL
100mm acetate buffer	365 uL	746 uL
25 calcitonin stock sol'n 10,000 U/mL	8 uL	-----
<b>Total volume</b>	<b>2.0 mL</b>	<b>4.0 mL</b>

**Test Method**

Each test group contained five animals (juvenile male rats, Sprague-Dawley rats approx. 140-170 gm). Group 30 A1, B1 and C1 received 250 uL of the respective microemulsion, 40U/ml calcitonin; the controls received 250 uL of the control microemulsion.

The animals were orally gavaged with melted microemulsion and then quickly anaesthetized and a blood

- 45 -

sample was taken via the orbital sinus to establish a baseline ( $T_0$ ). After 120 min., a second blood sample was taken. The  $Ca^{2+}$  and  $PO_4$  levels were analyzed in both samples and compared to determine the activation and uptake 5 of the drug. Serum  $Ca^{2+}$  (free ionized calcium) levels were determined using a Beckman 700 calcium clinical assay kit along with serum  $PO_4$  levels.

#### Results

The results of this study are shown in the table 10 below which summarizes the activity of microemulsions A1, B1, and C1 and the controls A1', B1', and C1'. All microemulsion calcitonin formulations showed statistically significant reductions in both  $Ca^{2+}$  and  $PO_4$  serum levels, except that the C1 emulsion system did not show such 15 activity for reduction of  $Ca^{2+}$ . The 'P' value is a statistical quantity that refers to the probability that the treatment and control values are equal. A 'P' value of 0.05 represents a one-in-twenty chance that the groups are equal. Therefore, 'P' values below 0.05 are considered 20 statistically significant.

5

SUMMARY OF SERUM CALCIUM AND PHOSPHATE CHANGES  
INDUCED BY ORAL GAVAGE OF RATS WITH MICROEMULSIONS  
CONTAINING HIGH MELTING POINT TRIGLYCERIDES

WITH OR WITHOUT CALCITONIN

Formu- lation	Trigly- ceride	MRC U/mL	Ca <sup>2+</sup> Diff. mg/dL	'P' Value calcitonin vs. Control	'P' Value Po <sub>4</sub> Diff. mg/dL vs. 2HR		'P' Value Calcitonin vs. Control
					Po <sub>4</sub>	2HR	
10	A1	HB-108	40	-0.62	---	-2.8	
	A1'	HB-108	0	-0.14	0.029	-0.8	0.010
	B1	HB-95	40	-1.58	---	-2.6	
	B1'	HB-95	0	0.82	0.036	-0.2	0.003
	C1	HB-118	40	2.08	---	-2.6	
15	C1'	HB-118	0	0.08	0.880	0.0	0.005

'P' Values < 0.05 are considered significant

- 47 -

**EXAMPLE 15**

A series of experiments was carried out using rats with the w/o microemulsion of this invention to evaluate the performance between solid formulations and liquid 5 formulations using the peptide salmon calcitonin (used in the treatment of hypercalcemia by lowering Ca<sup>2+</sup> serum levels) via oral administration. The body fluids of the rat served to convert the microemulsion to an o/w emulsion which activated the drug and promoted drug uptake by the 10 animal. The serum Ca<sup>2+</sup> was monitored to evaluate the effectiveness of the microemulsion carrier system.

**Formulations**

The solid test preparations were prepared using a high melting point oil, in this case a mixture of 15 hydrogenated coconut and palm oil, HB-108 (HYDROKOTE 108) which had a melting point of 108°F.

The A and B group microemulsions (ME) were prepared as liquid microemulsions at room temperature. The A ME was the liquid control and did not contain calcitonin. The 20 group B ME was the liquid calcitonin sample. The C and D ME were prepared as solids at room temperature by first formulating the microemulsion and then admixing the HB-108 oil with the microemulsion. The microemulsion components were mixed in a container at an elevated temperature of 25 about 40°C to which was added the calcitonin contained in the acetate buffer. Once the microemulsion was formed, the HB-108 component containing 10% Capmul was added. The C ME was the control solid ME and the D ME was the calcitonin sample.

- 48 -

## FORMULATIONS

Dose	Group A Control	Group B 40 U/mL Calcitonin		Group C* Control	Group D* 40 U/mL Calcitonin
		157 uL	57 uL		
5 Capmul MCM	157 uL	157 uL	57 uL	57 uL	57 uL
Captex 200	1.413mL	1.413 mL	513 uL	513 uL	513 uL
Centrophase 31 (lecithin)	35 uL	35 uL	35 uL	35 uL	35 uL
Cremophor EL	298 uL	298 uL	298 uL	298 uL	298 uL
10 Saline	100 ul	92 uL	100 ul	92 uL	92 uL
Salmon Calcitonin 10,000 U/mL	----	8 uL	----	8 uL	8 uL
HB-108**	----	----	0.9 mL	0.9 mL	0.9 mL
Capmul MCM**	----	----	0.1 mL	0.1 mL	0.1 mL
15 Total Volumes	2 mL	2 mL	2 mL	2 mL	2 mL

\* The suppository base contained small amounts of Methylparaben, Propylparaben and BHT.

\*\* The C and D ME were prepared first and these suppository base components added thereto to formulate the final ME which were solid at room temperature.

## Test Method

Each test group contained four animals (juvenile male rats, Sprague-Dawley rats approx. 110 gm). Groups B and D received 250 uL of the respective microemulsion, 10U/ml calcitonin; the controls received 250 uL of the control microemulsion.

The animals were orally gavaged with the liquid ME and melted solid ME and then quickly anaesthetized and a blood sample was taken via the orbital sinus to establish a baseline. After 120 min., a second blood sample was taken. The Ca<sup>2+</sup> level was analyzed in both samples and compared to determine the activation and uptake of the drug. Serum Ca<sup>2+</sup>

- 49 -

(free ionized calcium) levels were determined using a Beckman 700 calcium clinical assay kit.

**Results**

The results of this study are shown in the table 5 below which summarizes the activity of microemulsions A, B, C, and D. The serum  $\text{Ca}^{2+}$  level after 120 min. was found to be significantly reduced, when compared to the control, in only the solid microemulsion formulation, ME D. The serum  $\text{Ca}^{2+}$  level was not significantly reduced using the liquid 10 calcitonin sample, ME B, when compared to the control.

**SUMMARY OF SERUM CALCIUM LEVELS TWO HOURS AFTER  
GAVAGE WITH LIQUID OR MELTED SOLID MICROEMULSIONS  
WITH OR WITHOUT SALMON CALCITONIN IN THE AQUEOUS PHASE**

15	Group	Treatment	Calcitonin MRC U/mL	Serum $\text{Ca}^{2+}$			'P'Diff.
				2Hr Postdose	SD		
	A	Liquid ME	0	13.9	2.75		----
	B	Liquid ME	40	12.2	0.82		0.860
	C	Solid ME	0	13.5	2.89		----
20	D	Solid ME	40	9.0	2.70		0.033

'P' Values < 0.05 are considered significant.

**EXAMPLE 16**

Stable w/o microemulsion formulations were prepared which, upon conversion with additional water, form o/w 25 microemulsions. The w/o microemulsions were formulated with a sorbitol in saline solution which allowed for the formation of the w/o microemulsion at higher HLB values than those required to form a w/o microemulsion without the presence of the sorbitol solution. The higher HLB value 30 allows for the system to convert into an o/w microemulsion.

Sample w/o microemulsions which convert to o/w micro emulsions were prepared according to the systems described below. The HB-95 component is a purified coconut and palm oil mixture manufactured by Karlshamns Lipid 35 Specialties of Columbus, OH, having a melting point of

- 50 -

95°F. Myverol 18-92 is a surfactant having an HLB = 4 and is manufactured by Eastman Chemicals. Capmul MCM is a surfactant having an HLB = 5.5-6.0 and is manufactured by Karlshamns Lipid Specialties. Tween 80 is a surfactant having an HLB = 15 and was purchased from Spectrum Chemicals. The sorbitol was dissolved in a saline solution of 0.15 M NaCl. The HLB was determined using a volume average. The temperature was the temperature at which the microemulsion was formed.

10 The number average particle size of the converted microemulsion ranged from about 20 to about 70 nanometers. The amount of water used to convert the w/o microemulsion to the o/w microemulsion ranged from about 10 to about 1000 times the amount of the original w/o microemulsion volume.

## w/o Converting to o/w Microemulsion Formulations

5 Sample ID	HB-95 ( $\mu$ l)	Captox 200 ( $\mu$ l)	Myverol 18-92 ( $\mu$ l)	Capmul MCM ( $\mu$ l)	20% Sorbitol in saline ( $\mu$ l)		30% Sorbitol in saline ( $\mu$ l)		Temp. ( $^{\circ}$ C)
					Tween 80 ( $\mu$ l)	HLB	Tween 80 ( $\mu$ l)	HLB	
A	--	700	130	90	650	360	--	12.4	25
B	700	--	130	90	650	--	360	12.4	40
C	400	300	140	160	570	460	--	11.5	37
D	400	300	100	160	610	460	--	12.0	37
E	400	300	60	160	650	460	--	12.5	37

- 52 -

**EXAMPLE 17**

A series of experiments was carried out using rats with the w/o microemulsion of this invention to evaluate them as a vehicle for the delivery of the human growth 5 hormone, hGH. The body fluids of the rats served to convert the microemulsion to an o/w emulsion which activated the drug and promoted drug uptake across the mucosal membrane of the rat colon.

**Formulations**

10 The test microemulsion systems were prepared as set forth below. Group A was a suppository formulation made with a microemulsion formulation of the present invention. The Group A microemulsion was made first as a liquid and then dispersed within a high melting oil. The other groups 15 were buffer solutions and not microemulsions.

**Group A**

Captex 200	1.14ml
with 10% Capmul MCM	
Lecithin	0.07ml
20 Cremophor EL	0.59ml
hGH in sterile H <sub>2</sub> O	0.20ml
HB-108 with	2.00ml
10% Capmul MCM	

Group A contained 0.096U hGH/ml. Group B was a 5mM 25 NaPO<sub>4</sub> buffer solution at pH=7.8 with 0.096U hGH/ml. Group C was a 5mM NaPO<sub>4</sub> buffer solution at pH=7.8 with 0.024U hGH/ml. Group D contained no hGH and was a 5mM NaPO<sub>4</sub> buffer solution at pH=7.8.

**Test Method**

30 Test rats were divided into four groups: A, B, C, and D. Groups A, B, and C received the extracted growth hormone while group D was a control and did not receive the hormone. The rats were approximately 100 grams and were fasted for 24 hours prior to testing.

35 The dosage and group size is shown in the table below. The injected group, Group C, received the extracted

- 53 -

hGH in a buffer solution at the human equivalent dose of 0.05 mg/kg body weight. The two rectal administration groups, Groups A and B, received ten times the human equivalent dose.

5	<u>Group</u>	<u>ROUTE</u>	<u>(Vol/dosage form)</u>	<u>[Drug]/rat</u>	<u>No.</u>
	A	Rectal	250 ul/supp.	.024 Units	18
	B	Rectal	250 ul buffer	.024 Units	12
	C	SQ	100 ul buffer	.0024 Units	12
	D	Control	0	0	2

10           The rats were anaesthetized just prior to dosing. Suppositories (Group A) and the buffer solution (Group B) administered rectally were sealed in the rectum by a plug and liquid cement. Group C animals were injected subcutaneously (SQ). After administering the dosage, serum 15 hGH levels were determined at 30, 60, 120, 180, 240, and 300 minutes. Three animals from Group A were used per data point. Two animals from Groups B and C were used per data point. Two animals were used at 0 minutes for a baseline in the control group, Group D. The blood samples were 20 taken from the orbital sinus. The blood was centrifuged and the serum assayed by hGH ELISA (Medix Lab, Foster City, CA) for quantitation of the extracted growth hormone.

#### Results

At ten times the human equivalent dose level, the 25 suppository formulations (Group A) showed an equivalent bioavailability to the injected dose (Group C). The AUC (area under the curve) for both routes of administration was determined using the trapezoid rule (M. Gibaldi, *Biopharmaceutics and Clinical Pharmacokinetics*, Lea and Febiger, Philadelphia, PA, 1984, pp. 315-16). The AUC was approximately 24.5 ng-hr/ml for both the SQ injection and the suppository. The hGH in buffer that was administered rectally at the same dose as the suppository formulation showed no uptake of the drug. The bioavailability of the 30

- 54 -

suppository formulation was about 10% as compared to an inject d dose.

	<u>Time (min)</u>	<u>Injected hGH(Group C)</u> <u>(ng/mL)</u>	<u>SD</u>	<u>Suppository hGH(Group A)</u> <u>(ng/mL)</u>	<u>SD</u>
5	30	16.5	5.00	16.000	4.360
	60	10.0	0.00	14.700	8.330
	120	6.0	1.40	2.000	2.000
	180	2.5	2.12	1.670	1.160
	240	0.5	0.71	1.670	0.580
	300	0.0	0.00	0.333	0.577

Injected n=2; suppository n=3

#### EXAMPLE 18

Experiments were carried out using rats with the w/o 15 microemulsion of this invention to evaluate them as a vehicle for the delivery of the peptide cyclo(S,S)-N<sup>a</sup>-acetyl-Cys-(N<sup>a</sup>-methyl) Arg-Gly-Asp-Pen-NH<sub>2</sub>.

#### Formulations

The test microemulsion systems were prepared 20 according to the methods of the application with the peptide added to the system last.

- 55 -

## COMPOSITIONS OF THE MICROEMULSIONS (WEIGHT %)

COMPONENT (WT%)	ME-1	ME-2	ME-3	ME-4	ME-5	ME-6
5	CAPTEX 200	68.30	76.47	76.91	76.57	76.65
	MYVACET	8.31	9.09	9.26	9.28	9.26
	CAPMUL MCM			0.96		
	DICAPRIN			2.13		
	CENTROPHASE 31	1.60	1.61	1.04		
	MYVEROL 18-92			9.82	10.01	1.06
	CREMOPHOR EL	16.52	16.63			10.00
	TWEEN 80				8.74	
SALINE (PEPTIDE)		5.26	5.30	3.13	3.19	3.20
						3.19

## T st M th d

Intravenous (i.v.) Administration: Fasted rats were anesthetized with an intraperitoneal (i.p.) injection and surgically fitted with a jugular catheter (ACUC protocol #90-151). Rats were allowed to recover from the surgery for 1 day. Catherized rats were fasted for 18 hr prior to the experiment. Each rat received either a 1 mg or 3 mg peptide/kg dose by lateral tail-vein administration. Blood samples of 0.5 ml aliquots were collected at 0, 1, 3, 5, 10, 15, 30, 45, 60, 90, 120, 150, and 180 min. The 0 min sample was taken 15 min prior to administration of the dose. Plasma was removed from the whole blood by centrifugation at 1600 x g for 5 min, and then plasma was stored at -20°C in 250 µl aliquots per sample. The blood pellet was reconstituted with 12.5 units heparinized saline and returned to the appropriate rat via the jugular catheter. After the experiment, rats were euthanized with i.v. administration of pentobarbital.

Intraduodenal (i.d.) Adminstration: Fasted rats were administered an i.p. injection of anesthesia cocktail and surgically fitted with jugular and duodenal catheters. Rats were allowed to recover from the surgery for 4-5 days (ACUC protocol #91-055). Catherized rats were fasted 18-20 hr prior to the experiment. Each group of rats received either 10 mg peptide/kg in each microemulsion (3.3 ml/kg) or 6.5 mg peptide/kg in each microemulsion (3.3 ml/kg). A saline control was administered to a group of rats containing 10 mg peptide/kg in a saline solution. Blood samples of 0.5 ml aliquots were collected via jugular catheter in heparinized eppendorf tubes at 0, 10, 30, 60, 120, 180, 240, and 1440 min. The 0 min sample was taken 15 min prior to administration of the dose by duodenal catheter. Plasma was collected for analysis and the blood turned to rats as described in the i.v. administration protocol. After 24 hr, rats were euthanized by i.v. administration of pentobarbital, exsanguinated, and a

- 57 -

macroscopic observation of the intestinal tract was performed.

Post-Column HPLC Fluorescence Assay: For samples and standards, plasma components were precipitated with 0.6 ml 5 cetonitrile, and then pelleted by centrifugation at 16,000 x g for 20 min. The supermatant was removed, and then dried to powder under N<sub>2</sub> at 40°C. Powder was dissolved in 0.5 ml 1% TFA solution, and then processed by solid-phase extraction procedure (SPEP). SPEP was as follows: 1) 10 condition 1 ml C<sub>18</sub> columns with methanol, and then rinse columns with 1 ml water, 2) standards and samples were applied to columns, and then rinsed twice with 1 ml water, 3) standards and samples were collected in tubes upon elution from column with methanol by two 0.5 ml aliquots. 15 The samples and standards were dried to powder under N<sub>2</sub> at 40°C, and then dissolved in 100 µl of 10% methanol: 90% ultrapure water solution. Standards and samples were placed in HPLC vials. Vials with standards were placed before and after vials containing the samples for HPLC 20 analysis. For the peptide standards, an aliquot was injected for analysis based on the concentration of the standard as follows: 50 µl aliquot was injected for analysis by post-column fluorescence detection. 25 Fluorescence chromatography data were collected and integrated using Nelson Chromatography Data System. The peak area ratio (Y) and peptide standard concentration (X) were used to determine the slope of a line which was forced through the origin from the equation: slope=(sum of X\*Y)/(sum of X<sup>2</sup>). The slope represented the relationship 30 between peak area ratio and peptide plasma concentration for the samples.

#### Results

The area under the plasma concentration curve (AUC) was determined for each test group. The percentage 35 bioavailability was determined by the equation with the average AUC from iv administration:

$$[(AUC_{id}/AUC_{iv}) * (mg/kg_{iv}/mg/kg_{id})] * 100.$$

The summary of the

- 58 -

results are listed below in which the microemulsion formulations of the present invention showed a significant increase in the bioavailability of the peptide in comparison to the saline solution.

FORMULATION	DOSE (mg/kg)	N	AUC <sup>1</sup>	BAC <sup>2</sup> (%)
SALINE	10.0	3	0.011 ± 0.005	0.5 ± 0.3
5 ME-1	6.5	3	0.405 ± 0.099	29.1 ± 7.1
ME-2	6.5	3	0.269 ± 0.164	19.4 ± 11.8
ME-3	10.0	3	0.115 ± 0.042	5.4 ± 2.2
ME-4	10.0	3	0.054 ± 0.04	2.5 ± 1.9
ME-5	10.0	1	0.8	7.4
10 ME-6	10.0	3	0.308 ± 0.094	14.4 ± 4.4

<sup>1</sup> Area under the curve (mg\*min/ml)

<sup>2</sup> Bioavailability relative to i.v. injected peptide

- 60 -

#### EXAMPLE 19

A w/o microemulsion according to ME-1 from Example 18 was formulated with the growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>. The composition of the

5 microemulsion was:

Captex 200	68.3% w/w
Capmul MCM	8.3% w/w
Centrophase 31	1.6% w/w
Cremophor EL	16.5% w/w
Aqueous	5.3% w/w

10

The aqueous solution contained 25.43 mg peptide/ml.

#### EXAMPLE 20-24

A w/o microemulsion according to ME-2, ME-3, ME-4, ME-5, and ME-6 from Example 18 is formulated with the 15 growth hormone releasing peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub> at both about 25mg/ml and 75 mg/ml of the aqueous medium.

#### EXAMPLE 25

Various phase diagrams were prepared by mixing the 20 surfactants in the weight ratios indicated in the following figures and then mixing the surfactant mixture with the oil in various weight ratios. The oil/surfactant mixtures were then titrated with increasing amounts of a 0.9% w/w saline solution. The experiments were carried out at room 25 temperature, 22-23°C, unless indicated otherwise. The water-in-oil microemulsion regions were stable for at least 24 hours as determined by maintaining a single phase system. The presence of liquid crystalline phases was determined by examination of the samples between crossed 30 polarizers, these systems were not defined in the figures as water-in-oil microemulsions.

The components of the water-in-oil microemulsions are:

35 Captex 200 - propylene glycol esters of capric/caprylic acids (Karlshamas Lipid Specialties, Columbus, OH)

- 61 -

Capmul MCM - mono-2nd diglycerides of medium-chain fatty acids (capric and caprylic) (Karlshamas Lipid Specialties, Columbus, OH) (HLB=5.0)

5 Cremophor EL - polyoxyethylene glycerol triricinoleate 35 DAC (BASF, Inc.) (HLB=13.5)

Myverol 18-92 - glycerol monolinoleate (HLB=3.8-4.0)

Centrophase 31 - lecithin (mol. wt. - 800) (Central Soya, Fort Wayne, IN) (HLB=4.0)

10 Tween 80 - polyoxyethylene-sorbitan monooleate, Sigma Corp. (HLB=15)

Whitepsol H-15 - a 90:10% Wt. mixture of triesters: diesters of glycerol and lauric acid with less than 2% wt. monoglycerides, m.p. 33-36°C.

15

In FIG. 1, the region defined as "A" is the water-in-oil microemulsion region while the region defined as "B" is a micelle solution region. In Fig. 1, the oil is Captex 200, the aqueous phase is a 0.9% wt. NaCl aqueous solution, and the surfactant mixture is Capmul MCM:Myverol 18-92:Cremophor EL in a weight ratio of 45.5:5.2:49.2. ME-6 from Example 18 is included within this phase diagram.

In Fig. 2 the oil is Captex 200, the aqueous phase is 0.9% wt. NaCl aqueous solution, and the surfactant mixture is Capmul MCM:Centrophase 31:Tween 80 in a weight ratio of 46:10.6:43.4.

In Fig. 3 the oil is Captex 200, the aqueous phase is 0.9% wt. NaCl aqueous solution, and the surfactant mixture is Capmul MCM:Centrophase 31:Cremophor EL in a weight ratio of 31.5:6:62.5. This system includes the ME-1 used in Example 18.

In Fig. 4 the oil is Whitepsol H-15, the aqueous phase is a 20% wt. Sorbitol in 0.9% wt. NaCl aqueous solution, and the surfactant mixture is Capmul MCM:Myverol 18-92:Tween 80 in a weight ratio of 15.4:8.5:76.

In Fig. 5 the oil is MYVACET 9-45K, the aqueous phase is 0.9% wt. NaCl aqueous solution, and the surfactant

- 62 -

mixture is Capmul MCM:Myverol 18-92:Cremophor EL in a weight ratio of 45.5:5.2:49.2.

**EXAMPLE 26**

Water-in-oil microemulsions depicted in Figs. 1-5 5 can be made using both about 25 mg peptide/ml and 75 mg peptide/ml aqueous phase using both peptides cyclo(S,S)-N<sup>2</sup>-acetyl-Cys-(N<sup>2</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub>) and His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>).

- 63 -

What we claim is:

1. A water-in-oil microemulsion, comprising:
  - (a) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, therapeutic water-soluble material;
  - (b) a continuous oil phase comprising at least one pharmaceutically acceptable oil; and
  - (c) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from about 7 to 14, wherein the active material is selected from the group consisting of calcitonins, insulins, fibrinogen antagonists, growth hormone releasing peptides, interleukins, erythropoietins, colony stimulating factors, RGD peptides, hematoregulatory peptides, vasopressin, collagenase inhibitors, angiotensin inhibitors, mammalian growth hormones, erythropoietins, heparins, interleukins, clotting factors, colony stimulating factors, hypothalamic releasing peptides, tissue plasminogen activators, atrial natriuretic peptides, tumor necrosis factor.
2. The composition of claim 1 wherein the oil phase comprises an oil component selected from the group consisting of triesters of glycerol having from about 9 to 25 carbon atoms, and diesters of propylene glycol having from about 7 to 55 carbon atoms.
3. The composition of claim 2 wherein the surfactant or mixture of surfactants is selected from the group consisting of cetyltrimethylammonium bromide, cetylpyridinium chloride and other salts; C<sub>8-32</sub> fatty acids and salts thereof; cholic acid and derivatives thereof such as deoxycholate, and its salts, ursodeoxycholic acid, and taurocholic acid; C<sub>8-56</sub> diesters of tartaric acid; phospholipids such as phosphatidic acid and phosphatidyl serine; C<sub>5-29</sub> monoesters of lactic acid; C<sub>8-20</sub> sulfonates,

- 64 -

including alkyl-, olefin-, and alkylaryl derivatives; tridecyl- and dodecylbenzene sulfonic acids; and C<sub>5-33</sub> sarcosine and betaine derivatives; phosphatidylethanolamine, sphingomyelins, ethoxylated 5 castor oil; C<sub>5-29</sub> mono-glycerides and ethoxylated derivatives thereof; C<sub>15-60</sub> diglycerides and polyoxyethylene derivatives thereof having 1 to 90 POE groups; C<sub>10-40</sub> esters of long chain fatty acids; C<sub>10-40</sub> alcohols; C<sub>8-96</sub> ethoxylated fatty esters; C<sub>14-130</sub> sucrose fatty esters; and C<sub>20-130</sub> sorbitol and 10 sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups.

4. The composition of claim 3 wherein the microemulsion contains a modifier in the aqueous phase 15 wherein the modifier is selected from the group consisting of sorbitol, polyethylene glycol, propylene glycol, mannitol, and mono- and disaccharides and is present in an amount sufficient to cause the water-in-oil microemulsion to convert to an oil-in-water microemulsion upon the 20 addition of aqueous medium.

5. The composition of claim 3 wherein the oil phase consists essentially of diesters of propylene glycol having from about 7 to 55 carbon atoms.

6. The composition of claim 3 wherein the 25 hydrophilic-lipophilic balance of the surfactant or surfactant mixture is from about 8 to 13.

7. The composition of claim 6 wherein the surfactant or mixture of surfactants is selected from the group consisting of C<sub>5-29</sub> monoglycerides, C<sub>15-60</sub> diglycerides, 30 C<sub>8-96</sub> ethoxylated fatty esters, C<sub>20-130</sub> sorbitol and sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups.

- 65 -

8. The composition of claim 4 or 7 wherein the volume percents of the water-in-oil microemulsion is from about 0.1 to about 15 for the aqueous phase; from about 50-90 for the oil phase; and from about 2-50 for the 5 surfactant or surfactant mixture.

9. The composition of claims 3, 4 or 8 wherein the active material is a fibrinogen antagonist.

10. The composition of claim 9 wherein the active agent is a peptide having the sequence cyclo(S,S)-N<sup>a</sup>-acetyl-10 Cys-(N<sup>a</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub>.

11. The composition of claims 3, 4 or 8 wherein the active material is a growth hormone releasing peptides.

12. The composition of claim 11 wherein the active agent is a peptide having the sequence His-D-Trp-Ala-Trp-D-15 Phe-Lys-NH<sub>2</sub>.

13. The composition of claims 3, 4 or 8 wherein the active agent is selected from the group consisting of calcitonins, insulins, and human growth hormones.

14. A water-in-oil microemulsion, comprising:  
20 (a) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, therapeutic water-soluble material;  
25 (b) a continuous oil phase consisting essentially of diesters of propylene glycol having from about 7 to 55 carbon atoms and triesters of glycerol having from about 9 to 83 carbon atoms; and  
30 (c) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from about 7 to 14.

- 66 -

15. The composition of claim 14 wherein the biologically active material is a protein, peptide, immunogen, or pharmaceutically-active material and wherein the oil phase consists of diesters of propylene glycol  
5 having from about 7 to 55 carbon atoms.

16. The composition of claim 15 wherein the active material is a protein or peptide and wherein the water:oil partition coefficient of the active agent is greater than 10:1.

10 17. The composition of claim 16 wherein the surfactant or mixture of surfactants is selected from the group consisting of cetyltrimethylammonium bromide, cetylpyridinium chloride and other salts; C<sub>8-32</sub> fatty acids and salts thereof; cholic acid and derivatives thereof such  
15 as deoxycholate, and its salts, ursodeoxycholic acid, and taurocholic acid; C<sub>8-56</sub> diesters of tartaric acid; phospholipids such as phosphatidic acid and phosphatidyl serine; C<sub>5-29</sub> monoesters of lactic acid; C<sub>8-20</sub> sulfonates, including alkyl-, olefin-, and alkylaryl derivatives;  
20 tridecyl- and dodecylbenzene sulfonic acids; and C<sub>5-33</sub> sarcosine and betaine derivatives; phosphatidylethanolamine, sphingomyelins, ethoxylated castor oil; C<sub>5-29</sub> mono-glycerides and ethoxylated derivatives thereof; C<sub>15-60</sub> diglycerides and polyoxyethylene derivatives  
25 thereof having 1 to 90 POE groups; C<sub>10-40</sub> esters of long chain fatty acids; C<sub>10-40</sub> alcohols; C<sub>8-96</sub> ethoxylated fatty esters; C<sub>14-130</sub> sucrose fatty esters; and C<sub>20-130</sub> sorbitol and sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90  
30 POE groups.

18. The composition of claim 17 wherein the hydrophilic-lipophilic balance of the surfactant or surfactant mixture is from about 8 to 13.

- 67 -

19. The composition of claims 17 wherein the microemulsion contains a modifier in the aqueous phase wherein the modifier is selected from the group consisting of sorbitol, polyethylene glycol, propylene glycol, 5 mannitol, and mono- and disaccharides and is present in an amount sufficient to cause the water-in-oil microemulsion to convert to an oil-in-water microemulsion upon the addition of aqueous medium.

20. The composition of claim 17 wherein the non-  
10 aqueous phase is essentially free of sterols.

21. The composition of claim 17 wherein the surfactant or surfactant mixture contains at least one surfactant having an HLB value below about 5 and at least one surfactant having an HLB value above about 9.

15 22. The composition of claim 17 or 19 wherein the volume percents of the water-in-oil microemulsion is from about 0.1 to about 15 for the aqueous phase; from about 50-90 for the oil phase; and from about 2-50 for the surfactant or surfactant mixture.

20 23. The composition of claim 22 wherein the particle size is below about 150 nanometers.

24. The composition of claim 23 wherein the surfactant or mixture of surfactants is selected from the group consisting of C<sub>5-29</sub> monoglycerides, C<sub>15-60</sub> diglycerides, 25 C<sub>8-96</sub> ethoxylated fatty esters, C<sub>20-130</sub> sorbitol and sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups.

25. The composition of claims 17, 19 or 24 wherein the active material is a fibrinogen antagonist.

- 68 -

26. The composition of claim 25 wherein the active material is a peptide having the sequence cyclo(S,S)-N<sup>2</sup>-acetyl-Cys-(N<sup>2</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub>.

27. The composition of claims 17, 19 or 24 wherein  
5 the active material is a growth hormone releasing peptides.

28. The composition of claim 27 wherein the active material is a peptide having the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>.

29. The composition of claims 17, 19 or 24 wherein  
10 the active material is selected from the group consisting of calcitonins, insulins, fibrinogen antagonists, growth hormone releasing peptides, interleukins, erythropoietins, colony stimulating factors, RGD peptides, hematoregulatory peptides, vasopressin, collagenase inhibitors, angiotensin  
15 inhibitors, mammalian growth hormones, erythropoietins, heparins, interleukins, clotting factors, colony stimulating factors, hypothalamic releasing peptides, tissue plasminogen activators, atrial natriuretic peptides, tumor necrosis factor.

20 30. The composition of claim 29 wherein the active material is selected from the group consisting of calcitonins, insulins, and human growth hormones.

31. A water-in-oil microemulsion which is a solid at room temperature, comprising:

25 (a) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, therapeutic water-soluble material;  
30 (b) a continuous oil phase comprising at least one pharmaceutically-acceptable oil; and

- 69 -

(c) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from about 7 to 14.

32. The composition of claim 31 wherein the 5 biologically active material is a protein, peptide, immunogen, or pharmaceutically-active material.

33. The composition of claim 31 wherein the active material is a protein or peptide and the water:oil partition coefficient of the active material is greater 10 than 10:1.

34. The composition of claim 33 wherein the oil phase comprises an oil selected from the group consisting of triesters of glycerol having from about 9 to 83 carbon atoms, and diesters of propylene glycol having from about 7 15 to 55 carbon atoms.

35. The composition of claim 34 wherein the surfactant or mixture of surfactants is selected from the group consisting of cetyltrimethylammonium bromide, cetylpyridinium chloride and other salts; C<sub>8-32</sub> fatty acids 20 and salts thereof; cholic acid and derivatives thereof such as deoxycholate, and its salts, ursodeoxycholic acid, and taurocholic acid; C<sub>8-56</sub> diesters of tartaric acid; phospholipids such as phosphatidic acid and phosphatidyl serine; C<sub>5-29</sub> monoesters of lactic acid; C<sub>8-20</sub> sulfonates, 25 including alkyl-, olefin-, and alkylaryl derivatives; tridecyl- and dodecylbenzene sulfonic acids; and C<sub>5-33</sub> sarcosine and betaine derivatives; phosphatidylethanolamine, sphingomyelins, ethoxylated castor oil; C<sub>5-29</sub> mono-glycerides and ethoxylated derivatives 30 thereof; C<sub>15-60</sub> diglycerides and polyoxyethylene derivatives thereof having 1 to 90 POE groups; C<sub>10-40</sub> esters of long chain fatty acids; C<sub>10-40</sub> alcohols; C<sub>8-96</sub> ethoxylated fatty esters; C<sub>14-130</sub> sucrose fatty esters; and C<sub>20-130</sub> sorbitol and

- 70 -

sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups.

36. The composition of claim 35 wherein the 5 hydrophilic-lipophilic balance of the surfactant or surfactant mixture is from about 8 to 13.

37. The composition of claim 35 wherein the surfactant or surfactant mixture contains at least one surfactant having an HLB value below about 5 and at least 10 one surfactant having an HLB value above about 9.

38. The composition of claim 35 wherein the aqueous phase is from about 0.1 to about 20 volume percent of the microemulsion.

39. The composition of claim 38 wherein the oil 15 phase is from about 50-90 voulme percent of the microemulsion and the surfactant is from about 2-50 volume percent of the microemulsion.

40. The composition of claim 39 wherein the particle size is below about 150 nanometers.

20 41. The composition of claim 35 or 39 wherein the microemulsion contains a modifier in the aqueous phase wherein the modifier is selected from the group consisting of sorbitol, polyethylene glycol, propylene glycol, mannitol, and mono- and disaccharides and is present in an 25 amount sufficient to cause the water-in-oil microemulsion to convert to an oil-in-water microemulsion upon the addition of aqueous medium.

42. The composition of claim 41 wherein the oil is a diester of propylene glycol having from 19-23 carbon

- 71 -

atoms and the surfactant is a mixture of monoglycerides and diglycerides of capric and caprylic acid.

43. The composition of claims 35, 39 or 41 wherein the active material is selected from the group consisting of calcitonins, insulins, fibrinogen antagonists, growth hormone releasing peptides, interleukins, erythropoietins, colony stimulating factors, RGD peptides, hematoregulatory peptides, vasopressin, collagenase inhibitors, angiotensin inhibitors, mammalian growth hormones, erythropoietins, heparins, interleukins, clotting factors, colony stimulating factors, hypothalamic releasing peptides, tissue plasminogen activators, atrial natriuretic peptides, tumor necrosis factor.

44. The composition of claim 43 wherein the active material is selected from the group consisting of calcitonins, insulins, and human growth hormones.

45. The composition of claims 35, 39 or 41 wherein the active material is a fibrinogen antagonist.

46. The composition of claim 45 wherein the active material is a peptide having the sequence cyclo(S,S)-N<sup>a</sup>-acetyl-Cys-(N<sup>a</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub>.

47. The composition of claims 35, 39, or 41 wherein the active material is a growth hormone releasing peptides.

48. The composition of claim 47 wherein the active material is a peptide having the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>.

49. A method of administering to animals a biologically-active material which method comprises:  
(a) providing a water-in-oil microemulsion  
30 comprising:

- 72 -

(1) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, therapeutic water-soluble material;

5 (2) a continuous oil phase comprising at least one pharmaceutically-acceptable oil; and

(3) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from about 7 to 14, and

10 (b) administering an effective amount of the microemulsion to the body of an animal, wherein the water-in-oil microemulsion is administered parenterally, enterally, or via any other mucous membrane.

50. The method of claim 49 wherein the biologically active material is a protein, peptide, immunogen, or 15 pharmaceutically-active material.

51. The method of claim 49 wherein the active material is a protein or peptide, the water:oil partition coefficient of the active material is greater than 10:1 and 20 the particle size is below 150 nanometers.

52. The method of claim 51 wherein the oil phase comprises an oil selected from the group consisting of diesters of propylene glycol having from about 7 to 55 carbon atoms and triesters of glycerol having from about 25 9-83 carbon atoms.

53. The method of claim 52 wherein the surfactant or mixture of surfactants is selected from the group consisting of cetyltrimethylammonium bromide, cetylpyridinium chloride and other salts; C<sub>8-32</sub> fatty acids 30 and salts thereof; cholic acid and derivatives thereof such as deoxycholate, and its salts, ursodeoxycholic acid, and taurocholic acid; C<sub>8-56</sub> diesters of tartaric acid; phospholipids such as phosphatidic acid and phosphatidyl

- 73 -

serine;  $C_{5-29}$  mono st rs of lactic acid;  $C_{8-20}$  sulfonates, including alkyl-, olefin-, and alkylaryl derivatives; tridecyl- and dodecylbenzene sulfonic acids; and  $C_{5-33}$  sarcosine and betaine derivatives;

5 phosphatidylethanolamine, sphingomyelins, ethoxylated castor oil;  $C_{5-29}$  mono-glycerides and ethoxylated derivatives thereof;  $C_{15-60}$  diglycerides and polyoxyethylene derivatives thereof having 1 to 90 POE groups;  $C_{10-40}$  esters of long chain fatty acids;  $C_{10-40}$  alcohols;  $C_{8-96}$  ethoxylated fatty 10 esters;  $C_{14-130}$  sucrose fatty esters; and  $C_{20-130}$  sorbitol and sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups.

54. The method of claim 53 further comprising 15 converting the water-in-oil microemulsion to an oil-in-water emulsion by the addition of aqueous fluid.

55. The method of claim 54 wherein the conversion step is prior to the administration step.

56. The method of claim 54 wherein the water-in-oil 20 microemulsion converts to an oil-in-water microemulsion.

57. The method of claim 54 wherein the aqueous phase is from about 0.1 to about 20 volume percent of the water-in-oil microemulsion prior to the conversion step.

58. The method of claim 54 wherein the mixture of 25 surfactants comprises a surfactant with an HLB value of less than about 5 and a surfactant with an HLB value of at least 9.

59. The method of claim 57 wherein the surfactant is a mixture that contains (i) at least one surfactant 30 selected from the group consisting of  $C_9-C_{13}$  monoglycerides,  $C_{19}-C_{25}$  monoglycerides of mono- and poly unsaturated fatty

- 74 -

acids, C<sub>15</sub>-C<sub>23</sub> diglycerides, C<sub>35</sub>-C<sub>47</sub> diglycerides of mono- and poly unsaturated fatty acids and (ii) at least one surfactant selected from the group consisting of C<sub>20</sub>-C<sub>130</sub> sorbitol and sorbitan monoesters, diesters, and triesters 5 and polyoxyethylene derivatives thereof having from 0 to 90 oxyethylene groups.

60. The method of claim 54 wherein the water-in-oil microemulsion is solid at room temperature.

61. The method of claim 54 wherein oil phase 10 consists essentially of an oil selected from the group consisting of a diester of propylene glycol having from 7-31 carbon atoms and a triglyceride having from 9 to 45 carbon atoms.

62. The method of claims 51, 54, or 56 wherein the 15 active material is selected from the group consisting of calcitonins, insulins, fibrinogen antagonists, growth hormone releasing peptides, interleukins, erythropoietins, colony stimulating factors, RGD peptides, hematoregulatory peptides, vasopressin, collagenase inhibitors, angiotensin 20 inhibitors, mammalian growth hormones, erythropoietins, heparins, interleukins, clotting factors, colony stimulating factors, hypothalamic releasing peptides, tissue plasminogen activators, atrial natriuretic peptides, tumor necrosis factor.

25 63. The method of claim 62 wherein the active material is calcitonins, insulins, or human growth hormones.

64. The method of claim 51, 54, or 56 wherein the active material is a fibrinogen antagonist.

- 75 -

65. The method of claim 64 wherein the active material is a peptide having the sequence cyclo(S,S)-N<sup>a</sup>-acetyl-Cys-(N<sup>a</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub>.

66. The method of claims 51, 54, or 56 wherein the active material is a growth hormone releasing peptides.

67. The method of claim 66 wherein the active material is a peptide having the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>.

68. A water-in-oil microemulsion for the delivery of a biologically active therapeutic material, comprising:  
about 5-80% v/v of a composition containing a mixture of triesters:diesters of glycerol and lauric acid;  
about 15-50% v/v of polyoxyethylene sorbitan monooleate;  
about 3-11% v/v of a mixture of mono- and diglycerides of capric and caprylic acid;  
about 2-6% v/v of long chain monoglycerides;  
about 6-42% v/v of an aqueous 25% w/w sorbitol and 25% w/w propylene glycol solution containing a biologically active agent.

69. The composition of claim 68 wherein the active agent is selected from the group consisting of calcitonins, insulins, fibrinogen antagonists, growth hormone releasing peptides, interleukins, erythropoietins, colony stimulating factors, RGD peptides, hematoregulatory peptides, vasopressin, collagenase inhibitors, angiotensin inhibitors, mammalian growth hormones, erythropoietins, heparins, interleukins, clotting factors, colony stimulating factors, hypothalamic releasing peptides, tissue plasminogen activators, atrial natriuretic peptides, tumor necrosis factor.

- 76 -

70. The composition of claim 69 wherein the active material is calcitonins, insulins, or human growth hormones.

71. The composition of claim 68 wherein the active 5 material is a fibrinogen antagonist.

72. The method of claim 71 wherein the active material is a peptide having the sequence cyclo(S,S)-N<sup>2</sup>-acetyl-Cys-(N<sup>2</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub>.

73. The method of claim 68 wherein the active 10 material is a growth hormone releasing peptides.

74. The method of claim 73 wherein the active material is a peptide having the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>.

75. A water-in-oil microemulsion for the delivery 15 of a biologically active, therapeutic material wherein the relative proportions of oil phase, aqueous phase, and surfactant mixture are as described within area A of Figure 1 and wherein the aqueous phase comprises the active material.

76. The microemulsion of claim 75 wherein the active agent is selected from the group consisting of calcitonins, insulins, fibrinogen antagonists, growth hormone releasing peptides, interleukins, erythropoietins, colony stimulating factors, RGD peptides, hematoregulatory 25 peptides, vasopressin, collagenase inhibitors, angiotensin inhibitors, mammalian growth hormones, erythropoietins, heparins, interleukins, clotting factors, colony stimulating factors, hypothalamic releasing peptides, tissue plasminogen activators, atrial natriuretic peptides, 30 tumor necrosis factor.

- 77 -

77. The microemulsion of claim 76 wherein the active material is a peptide selected from cyclo(S,S)-N<sup>a</sup>-acetyl-Cys-(N<sup>a</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub> and His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>.

5 78. A water-in-oil microemulsion for the delivery of a biologically active, therapeutic material wherein the relative proportions of oil phase, aqueous phase, and surfactant mixture are as described within area of Figure 3, and wherein the aqueous phase comprises the active  
10 material.

79. The microemulsion of claim 78 wherein the active agent is selected from the group consisting of calcitonins, insulins, fibrinogen antagonists, growth hormone releasing peptides, interleukins, erythropoietins, 15 colony stimulating factors, RGD peptides, hematoregulatory peptides, vasopressin, collagenase inhibitors, angiotensin inhibitors, mammalian growth hormones, erythropoietins, heparins, interleukins, clotting factors, colony stimulating factors, hypothalamic releasing peptides, 20 tissue plasminogen activators, atrial natriuretic peptides, tumor necrosis factor.

80. The microemulsion of claim 79 wherein the active material is a peptide selected from cyclo(S,S)-N<sup>a</sup>-acetyl-Cys-(N<sup>a</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub> and His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>.  
25

81. A water-in-oil microemulsion for the delivery of a biologically active, therapeutic material, comprising about 76% wt. propylene glycol esters of capric and caprylic acids; about 5% wt. saline solution comprising the  
30 active material; and about 1.6% wt. of lecithin; and about 17% wt. polyoxyethylene glycerol triricinoleate.

- 78 -

82. The microemulsion of claim 81 wherein the active agent is selected from the group consisting of calcitonins, insulins, fibrinogen antagonists, growth hormone releasing peptides, interleukins, erythropoietins, 5 colony stimulating factors, RGD peptides, hematoregulatory peptides, vasopressin, collagenase inhibitors, angiotensin inhibitors, mammalian growth hormones, erythropoietins, heparins, interleukins, clotting factors, colony stimulating factors, hypothalamic releasing peptides, 10 tissue plasminogen activators, atrial natriuretic peptides, tumor necrosis factor.

83. The microemulsion of claim 82 wherein the active material is a peptide selected from cyclo(S,S)-N<sup>2</sup>-acetyl-Cys-(N<sup>2</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub> and His-D-Trp-Ala-15 Trp-D-Phe-Lys-NH<sub>2</sub>.

84. A method of storing biologically-active, therapeutic materials which comprises:

(a) providing a water-in-oil microemulsion comprising:

20 (1) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, therapeutic water-soluble material;

25 (2) a continuous oil phase comprising at least one pharmaceutically-acceptable oil; and

(3) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from about 7 to 14, and

30 (b) storing the water-in-oil microemulsion for at least one hour at about room temperature or above; and wherein the water:oil partition coefficient of the active material is greater than 10:1; and wherein the activity of said aqueous phase of said microemulsion is greater than the activity of said active

- 79 -

material that is stored in said aqueous phase alone but otherwise under the same conditions.

85. The method of claim 1 wherein the active material is a protein, peptide, immunogen, or 5 pharmaceutically-active material.

86. A method of treating a skin wound in which the epidermis is partially removed, comprising:

(a) applying to the wound a water-in-oil microemulsion comprising:

10 (1) an internal dispersed aqueous phase comprising an effective amount of a biologically-active, therapeutic water-soluble material, said material having an average particle size greater than the average particle size of epidermal skin pores,

15 (2) a continuous oil phase comprising at least one pharmaceutically-acceptable oil, and

20 (3) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of at least about 7, and

25 wherein the volume percent of the aqueous phase based on the total volume of the water-in-oil microemulsion is up to about 60 percent.

87. The method of claim 86 wherein the active material has an average molecular weight of at least about 5000 and wherein the active material is selected from the group consisting of protease enzymes and growth factors, 30 and the method further comprising converting the water-in-oil microemulsion to an oil-in-water emulsion by the addition of aqueous fluid.

- 80 -

88. A water-in-oil microemulsion for treating a skin wound comprising:

(a) an internal dispersed aqueous phase containing an effective amount of a biologically-active, therapeutic water-soluble material selected from the group consisting of protease enzymes and growth factors, said material having an average particle size greater than the average particle size of the epidermis skin pores,

(b) a continuous oil phase comprising at least one pharmaceutically-acceptable oil, and

(c) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of at least about 7, and

wherein the volume percent of water based on the total volume of the water-in-oil microemulsion is up to about 60 percent,

wherein the water:oil partition coefficient for the active material is greater than 10:1.

89. The microemulsion of claim 88 wherein the active material has an average molecular weight of at least about 5000 and wherein the particle size of the active material is from about 3 to about 100 nanometers.

## AMENDED CLAIMS

[received by the International Bureau on  
24 September 1992 (24.09.92); original  
claims 1-89 replaced by amended claims  
1-54; (14 pages)]

1. A water-in-oil microemulsion composition,  
comprising:

(a) up to about 60 volume percent, based upon the  
total volume of the microemulsion, of an internally dispersed  
5 aqueous phase comprising an effective amount of a  
biologically-active, therapeutic water-soluble material;

(b) from about 5 to 99 volume percent of a  
continuous oil phase comprising at least one pharmaceutically  
acceptable oil; and

10 (c) from about 1 to 70 volume percent of a  
surfactant or mixture of surfactants, wherein the surfactant  
or surfactant mixture has a hydrophilic-lipophilic balance  
value of from about 7 to 14,  
wherein the active material is selected from the  
15 group consisting of calcitonins, insulins, fibrinogen  
antagonists, growth hormone releasing peptides, interleukins,  
erythropoetins, colony stimulating factors, RGD peptides,  
hematoregulatory peptides, vasopressin, collagenase  
inhibitors, angiotensin inhibitors, mammalian growth  
20 hormones, erythropoetins, heparins, interleukins, clotting  
factors, colony stimulating factors, hypothalamic releasing  
peptides, tissue plasminogen activators, atrial natriuretic  
peptides, tumor necrosis factor, and wherein the water:oil  
partition coefficient of the active material is greater than  
25 10:1.

2. The composition of claim 1 wherein the oil  
phase comprises diesters of propyl ne glycol having from  
about 15 to 40 carbon atoms.

3. A water-in-oil microemulsion composition, comprising:

(a) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, water-soluble material;

(b) from about 5 to 99 volume percent of a continuous oil phase comprising diesters of propylene glycol having from 15 to 40 carbon atoms; and

(c) from about 1 to 70 volume percent of a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from about 7 to 14,

wherein the active material has a water:oil partition coefficient greater than 10:1.

4. The composition of claim 3 wherein the active material is a therapeutic and is a protein, peptide, immunogen, or other pharmaceutically-active material.

5. A water-in-oil microemulsion composition that is a solid at temperatures of about 23°C, comprising:

(a) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, water-soluble material;

(b) from about 5 to 99 volume percent of a continuous oil phase; and

(c) from about 1 to 70 volume percent of a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from about 7 to 14,

wherein the active material has a water:oil partition coefficient greater than 10:1, and wherein the oil phase, surfactant or mixture of surfactants, or both, comprises a component that has a melting point above about 23°C.

6. The composition of claim 5 wherein the active material is a therapeutic and is a protein, peptide, immunogen, or other pharmaceutically-active material.

7. The composition of claim 6 wherein the oil phase comprises a triglyceride having at least 45 carbon atoms, a propylene glycol diester having at least 31 carbon atoms, or mixtures thereof.

8. The composition of claim 6 wherein the water-in-oil microemulsion is disposed within an oil matrix that is solid at temperatures of about 23°C.

9. A water-in-oil microemulsion composition, comprising:

15 (a) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, water-soluble material, and a modifier, present in an amount sufficient to cause the water-in-oil

20 microemulsion to convert to an oil-in-water microemulsion upon the addition of aqueous medium;

(b) from about 5 to 99 volume percent of a continuous oil phase comprising at least one pharmaceutically acceptable oil; and

25 (c) from about 1 to 70 volume percent of a surfactant or mixture of surfactants, wherein the surfactant or mixture of surfactants has a hydrophilic-lipophilic balance value of greater than about 7.

10. The composition of claim 9 wherein the active 30 material is a therapeutic and is a protein, peptide, immunogen, or other pharmaceutically-active material.

- 84 -

11. The composition of claim 10 wherein the modifier comprises sorbitol, polyethylene glycol, propylene glycol, mannitol, monosaccharides or disaccharides.

12. The composition of claim 11 wherein the 5 modifier is 10-50 percent by weight of the aqueous phase of the water-in-oil microemulsion.

13. A water-in-oil microemulsion composition, comprising:

10 (a) up to about 20 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, water-soluble material;

15 (b) from about 30 to 99 volume percent of a continuous oil phase comprising triglycerides having from 9 to 83 carbon atoms, diesters of propylene glycol having from 15 to 40 carbon atoms, and mixtures thereof; and

20 (c) from about 1 to 70 volume percent of a surfactant or mixture of surfactants comprising a low HLB surfactant having an HLB value below about 8 and further comprising C<sub>5-28</sub> monoglycerides or phospholipids, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from about 7 to 14,

wherein the active material has a water:oil partition coefficient greater than 10:1 and

25 wherein the ratio of the oil phase to the low HLB surfactant is at least 6:1.

14. The composition of claim 13 wherein the active material is a therapeutic and is a protein, peptide, immunogen, or other pharmaceutically-active material, and

30 15. The composition of any of the claims 1-14 wherein the surfactant or mixture of surfactants is selected from the group consisting of cetyltrimethylammonium bromide, cetylpyridinium chloride and other salts; C<sub>8-32</sub> fatty

acids and salts thereof; cholic acid and derivatives thereof; C<sub>8-56</sub> diesters of tartaric acid; phospholipids; C<sub>5-29</sub> monoesters of lactic acid; C<sub>8-20</sub> sulfonates, including alkyl-, olefin-, and alkylaryl derivatives; tridecyl- and dodecylbenzene sulfonic acids; and C<sub>5-33</sub> sarcosine and betaine derivatives; 5 phosphatidylethanolamine, sphingomyelins, ethoxylated castor oil; C<sub>5-29</sub> mono-glycerides and ethoxylated derivatives thereof; C<sub>15-60</sub> diglycerides and polyoxyethylene derivatives thereof having 1 to 90 POE groups; C<sub>10-40</sub> esters of long chain 10 fatty acids; C<sub>10-40</sub> alcohols; C<sub>8-96</sub> ethoxylated fatty esters; C<sub>14-130</sub> sucrose fatty esters; and C<sub>20-130</sub> sorbitol and sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups.

16. The composition of any of the claims 1-12  
15 wherein the surfactant or mixture of surfactants comprises C<sub>9-13</sub> monoglycerides.

17. The composition of any of the claims 1-12  
wherein the oil phase comprises diesters of propylene glycol  
having from 19 to 23 carbon atoms and the surfactant or  
20 mixtures of surfactants comprises C<sub>9-13</sub> monoglycerides.

18. The composition of any of the claims 1-14  
wherein the hydrophilic-lipophilic balance of the surfactant  
or surfactant mixture is from about 8 to 13.

19. The composition of any of the claims 1-14  
25 wherein the surfactant or mixture of surfactants is selected  
from the group consisting of C<sub>9-13</sub> monoglycerides, C<sub>15-60</sub>  
diglycerides, C<sub>8-96</sub> ethoxylated fatty esters, C<sub>20-130</sub> sorbitol  
and sorbitan monoesters, diesters, and triesters, and  
polyoxyethylene (POE) derivatives thereof having 0 to 90 POE  
30 groups.

- 86 -

20. The composition of any of the claims 1-12 wherein the aqueous phase is from about 30 to about 60 volume percent of the water-in-oil microemulsion.

21. The composition of any of the claims 1-14 wherein the active material is a protein or a peptide.

22. The composition of any of the claims 1-14 wherein the active material is a fibrinogen antagonist.

23. The composition of claim 22 wherein the active material is a peptide having the sequence  $\text{cyclo}(\text{S},\text{S})-\text{N}^{\alpha}-$   
10 acetyl-Cys-( $\text{N}^{\alpha}$ -methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub>.

24. The composition of any of the claims 1-14 wherein the active material is a growth hormone releasing peptide.

25. The composition of claim 24 wherein the active material is a peptide having the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>.

26. The composition of any of the claims 1-14 wherein the active material is selected from the group consisting of calcitonins, insulins, and human growth hormones.

27. A method of storing biologically-active, therapeutic materials which comprises:

(a) providing a water-in-oil microemulsion composition comprising:

25 (1) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, water-soluble material comprising proteins or peptides;

- 87 -

(2) a continuous oil phase comprising at least one pharmaceutically-acceptable oil; and

(3) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of at least 7, and

(b) storing the water-in-oil microemulsion for at least one hour at about room temperature or above; and

wherein the water:oil partition coefficient of the active material is greater than 10:1; and

10 wherein the activity of said aqueous phase of said microemulsion is greater than the activity of said active material that is stored in said aqueous phase alone but otherwise under the same conditions.

28. A method of treating a skin wound in which the 15 epidermis is partially removed, comprising:

(a) applying to the wound a water-in-oil microemulsion composition comprising:

20 (1) an internal dispersed aqueous phase comprising an effective amount of a biologically-active, therapeutic water-soluble material, said active material having an average particle size greater than the average size of epidermal skin pores,

25 (2) a continuous oil phase comprising at least one pharmaceutically-acceptable oil, and

30 (3) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of at least about 7, and

wherein the volume percent of the aqueous phase based on the total volume of the water-in-oil microemulsion is up to about 60 percent.

- 88 -

29. The method of claim 28 wherein the active material has an average molecular weight of at least about 5000 and wherein the active material is selected from the group consisting of protease enzymes and growth factors.

5 30. A water-in-oil microemulsion composition for treating a skin wound, comprising:

10 (a) an internal dispersed aqueous phase containing an effective amount of a biologically-active, therapeutic water-soluble material selected from the group consisting of protease enzymes and growth factors, said active material having an average particle size greater than the average size of the epidermis skin pores,

15 (b) a continuous oil phase comprising at least one pharmaceutically-acceptable oil, and

20 (c) a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of at least 7, and

25 wherein the volume percent of water based on the total volume of the water-in-oil microemulsion is up to about 60 percent,

wherein the water:oil partition coefficient for the active material is greater than 10:1.

31. The microemulsion of claim 30 wherein the active material has an average molecular weight of at least about 5000 and wherein the particle size of the active material is from about 3 to about 30 nanometers.

32. A method of administering to animals a 30 biologically-active material which method comprises:

(a) providing a water-in-oil microemulsion composition comprising:

(1) up to about 60 volume percent, based upon the total volume of the micro emulsion, of an internally dispersed

- 89 -

aqueous phase comprising an effective amount of a biologically-active, water-soluble material;

(2) from about 1 to 70 volume percent of a continuous oil phase comprising diesters of propylene glycol 5 having from about 7 to 55 carbon atoms; and

(3) from about 1 to 70 volume percent of a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from 7 to 14, and

10 (b) administering an effective amount of the microemulsion to the body of an animal, wherein the water-in-oil microemulsion is administered parenterally, enterally, or via any mucous membrane.

33. The method of claim 32 wherein the active 15 material is a therapeutic and is a protein, peptide, immunogen, or other pharmaceutically-active material and the water:oil partition coefficient of the active material is greater than 10:1.

34. A method of administering to animals a 20 biologically-active material which method comprises:

(a) providing a water-in-oil microemulsion composition comprising:

(1) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed 25 aqueous phase comprising an effective amount of a biologically-active, water-soluble material;

(2) from about 5 to 99 volume percent of a continuous oil phase comprising at least one pharmaceutically-acceptable oil; and

30 (3) from about 1 to 70 volume percent of a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from 7 to 14, and

(b) administering an effective amount of the 35 microemulsion to the body of an animal, wherein the water-in-

- 90 -

oil micro mulSION is administered orally, rectally or via any mucous membrane.

35. The method of claim 34 wherein the active material is a therapeutic and is a protein, peptide, 5 immunogen, or other pharmaceutically-active material and the water:oil partition coefficient of the active material is greater than 10:1.

36. A method of administering to animals a biologically-active material which method comprises:

10 (a) providing a water-in-oil microemulsion composition comprising:

(1) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a 15 biologically-active, water-soluble material;

(2) from about 1 to 70 volume percent of a continuous oil phase comprising triglycerides having from 9 to 83 carbon atoms, diesters of propylene glycol having from about 15 to 40 carbon atoms, or mixtures thereof; and

20 (3) from about 1 to 70 volume percent of a surfactant or mixture of surfactants comprising C<sub>5-20</sub> monoglycerides or phospholipids, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of from 7 to 14, and

25 (b) administering an effective amount of the microemulsion to the body of an animal, wherein the water-in-oil microemulsion is administered parenterally, enterally, or via any mucous membrane.

37. The method of claim 36 wherein the active 30 material is a therapeutic and is a protein, peptide, immunog n, or other pharmaceutically-active material and the water:oil partition coeffici nt of the active material is greater than 10:1.

- 91 -

38. A method of administering to animals a biologically-active material which method comprises:

(a) providing a water-in-oil microemulsion composition comprising:

5 (1) up to about 60 volume percent, based upon the total volume of the microemulsion, of an internally dispersed aqueous phase comprising an effective amount of a biologically-active, water-soluble material, and a modifier, present in an amount sufficient to cause the water-in-oil 10 microemulsion to convert to an oil-in-water microemulsion upon the addition of aqueous medium;

(2) from about 5 to 99 volume percent of a continuous oil phase comprising at least one pharmaceutically-acceptable oil; and

15 (3) from about 1 to 70 volume percent of a surfactant or mixture of surfactants, wherein the surfactant or surfactant mixture has a hydrophilic-lipophilic balance value of at least 7, and

(b) administering an effective amount of the 20 microemulsion to the body of an animal, wherein the water-in-oil microemulsion is administered parenterally, enterally, or via any mucous membrane.

39. The method of claim 38 wherein the active material is a therapeutic and is a protein, peptide, 25 immunogen, or pharmaceutically-active material and the water:oil partition coefficient of the active material is greater than 10:1.

40. The method of claim 39 wherein the modifier comprises sorbitol, polyethylene glycol, propylene glycol, 30 mannitol, monosaccharides or disaccharides.

41. The method of claim 40 wherein the modifier is 10-50 percent by weight of the aqueous phase of the water-in-oil microemulsion.

- 92 -

42. The method of any of the claims 32-41 wherein the aqueous phase is up to about 20 percent by weight of the water-in-oil microemulsion.

43. The method of any of the claims 32-41 wherein 5 the oil phase comprises triesters of glycerol having from about 9 to 45 carbon atoms, diesters of propylene glycol having from about 19 to 23 carbon atoms, or mixtures thereof.

44. The method of any of the claims 32-41 wherein the surfactant or mixture of surfactants is selected from the 10 group consisting of cetyltrimethylammonium bromide, cetylpyridinium chloride and other salts; C<sub>8-32</sub> fatty acids and salts thereof; cholic acid and derivatives thereof such as deoxycholate, and its salts, ursodeoxycholic acid, and taurocholic acid; C<sub>6-56</sub> diesters of tartaric acid; 15 phospholipids such as phosphatidic acid and phosphatidyl serine; C<sub>5-20</sub> monoesters of lactic acid; C<sub>8-20</sub> sulfonates, including alkyl-, olefin-, and alkylaryl derivatives; tridecyl- and dodecylbenzene sulfonic acids; and C<sub>5-33</sub> sarcosine and betaine derivatives; phosphatidylethanolamine, 20 sphingomyelins, ethoxylated castor oil; C<sub>5-20</sub> mono-glycerides and ethoxylated derivatives thereof; C<sub>15-60</sub> diglycerides and polyoxyethylene derivatives thereof having 1 to 90 POE groups; C<sub>10-40</sub> esters of long chain fatty acids; C<sub>10-40</sub> alcohols; C<sub>8-96</sub> ethoxylated fatty esters; C<sub>14-130</sub> sucrose fatty esters; and 25 C<sub>20-130</sub> sorbitol and sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups.

45. The method of any of the claims 32-41 wherein the surfactant or mixture of surfactants is selected from the 30 group consisting of C<sub>9-13</sub> monoglycerides, C<sub>15-23</sub> diglycerides, C<sub>8-96</sub> thoxylated fatty esters, C<sub>20-130</sub> sorbitol and sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups.

- 93 -

46. The method of any of the claims 32-41 wherein the active material is a peptide having the sequence cyclo(S,S)-N<sup>α</sup>-acetyl-Cys-(N<sup>α</sup>-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub>.

47. The method of any of the claims 32-41 wherein 5 the active material is a peptide having the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>.

48. The method of any of the claims 32-41 wherein the active material is selected from the group consisting of calcitonins, insulins, fibrinogen antagonists, growth hormone 10 releasing peptides, interleukins, erythropoietins, colony stimulating factors, RGD peptides, hematoregulatory peptides, vasopressin, collagenase inhibitors, angiotensin inhibitors, mammalian growth hormones, erythropoietins, heparins, interleukins, clotting factors, colony stimulating factors, 15 hypothalamic releasing peptides, tissue plasminogen activators, atrial natriuretic peptides, tumor necrosis factor.

49. The method of any of the claims 32-41 wherein the active material is a protein or a peptide.

20 50. The method of any of the claims 32-41 wherein the water-in-oil microemulsion is a solid at a temperature of about 23°C.

51. The method of any of the claims 29 or 32-41 further comprising converting the water-in-oil microemulsion 25 to an oil-in-water emulsion by the addition of aqueous fluid.

52. The method of claim 51 wherein the conversion step is after the administration step and the aqueous fluid is body fluid.

- 94 -


53. The method of any of the claims 38-41 further comprising converting the water-in-oil microemulsion to an oil-in-water microemulsion by the addition of aqueous fluid.

54. The method of claim 53 wherein the conversion step is after the administration step and the aqueous fluid is body fluid.

- 95 -

**STATEMENT UNDER ARTICLE 19**

The claims 1-89 of the original application have been replaced by claims 1-54 submitted herewith. The replacement claims 1-54 more particularly define the preferred embodiments of the present invention. The claims are novel over the primary references, GB A 2,098,865 (GB 865) and GB 1,171,125 (GB 125) set forth in the search report.



**Fig. 1**

2/5






Fig. 2

3/5



**Fig. 3**

4/5



**Fig. 4**

5/5




Fig. 5

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/03086

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 37/02, 37/26, 37/43, 39/00  
US CL : 424/88, 400; 514/3, 12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/88, 400; 514/2, 3, 12, 937, 938, 940

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N .
X	GB, A, 2,098,865 (Franz) 01 December 1982, <u>page 2, lines 15-18 and 31-33.</u>	<u>75,78,84,85</u>
Y	page 3, lines 61-62, claims 4-8.	14,76,85
Y	US, A, 4,731,384 (Dell et al.) 15 March 1988, column 2, lines 21-29.	14
Y	"Kirk-Othmer Encyclopedia Of Chemical Technology", 3rd ed., Volume 8, published 1979 by John Wiley & Sons(N.Y.), pages 908, 913-918, 929.	1-67, 75-80, 84, 85
X	GB, A, 1,171,125 (Walton et al.) 19 November 1969.	<u>31-33,49-51, 75,78,84-</u>
Y	<u>page 2, lines 119-125, page 3, lines 6-16,</u> claims 1-3, 8-20.	<u>85</u> 1-30, 34-48, 52-67, 76, 77, 79, 80
Y,P	US, A, 5,037,653 (Dawson) 06 August 1991, column 2, lines 52-59.	1-67, 75-80, 84, 85
Y	US, A, 4,183,918 (Asher et al.) 15 January 1980, column 5, lines 24-45.	3,7,17,24, 35,53,59
Y	US, A, 4,241,051 (Christie et al.) 23 December 1980, column 1, line 66 - column 2, line 3.	76,85

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of actual completion of the international search

17 July 1992

Date of mailing of the international search report

24 JUL 1992

Name and mailing address of the ISA/  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

JEFFREY E. RUSSEL

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application N .  
PCT/US92/03086

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,931,210 (Takahashi et al.) 05 June 1990, Examples 6 and 7.	1-13,29,30, 43,44,62,63, 76,79

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*